KR102040364B1 - 알츠하이머병 관련 30개 유전자를 이용한 유전적 진단방법 - Google Patents

알츠하이머병 관련 30개 유전자를 이용한 유전적 진단방법 Download PDF

Info

Publication number
KR102040364B1
KR102040364B1 KR1020170065179A KR20170065179A KR102040364B1 KR 102040364 B1 KR102040364 B1 KR 102040364B1 KR 1020170065179 A KR1020170065179 A KR 1020170065179A KR 20170065179 A KR20170065179 A KR 20170065179A KR 102040364 B1 KR102040364 B1 KR 102040364B1
Authority
KR
South Korea
Prior art keywords
gene
unknown
mutation
protein
binding
Prior art date
Application number
KR1020170065179A
Other languages
English (en)
Other versions
KR20180130060A (ko
Inventor
안성수
김상윤
보반야우
에바바진스키
심규환
Original Assignee
가천대학교 산학협력단
서울대학교병원
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 가천대학교 산학협력단, 서울대학교병원 filed Critical 가천대학교 산학협력단
Priority to KR1020170065179A priority Critical patent/KR102040364B1/ko
Publication of KR20180130060A publication Critical patent/KR20180130060A/ko
Application granted granted Critical
Publication of KR102040364B1 publication Critical patent/KR102040364B1/ko

Links

Images

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2537/00Reactions characterised by the reaction format or use of a specific feature
    • C12Q2537/10Reactions characterised by the reaction format or use of a specific feature the purpose or use of
    • C12Q2537/143Multiplexing, i.e. use of multiple primers or probes in a single reaction, usually for simultaneously analyse of multiple analysis
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/118Prognosis of disease development
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/156Polymorphic or mutational markers
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/158Expression markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

본 발명은 알츠하이머 진단을 위한 정보제공방법 및 이를 이용한 진단키트에 관한 것이다. 본 발명의 방법을 이용한 유전자 돌연변이 분석결과에 따라 알츠하이머병 환자에게 개인적 맞춤 진단 및 치료가 가능할 것으로 기대된다. 본 발명의 방법을 이용하여 알츠하이머와 연관된 30개의 유전자를 스크리닝하여 환자가 가지고 있는 유전적 문제점을 확인한 후 개별 맞춤 치료를 적용할 수 있다.

Description

알츠하이머병 관련 30개 유전자를 이용한 유전적 진단방법{Genetic diagnostic method using 30 genes associated with Alzheimer's disease}
본 발명은 알츠하이머병의 유전적 진단방법 관한 것이다. 보다 상세하게는, 본 발명은 알츠하이머 환자에서 나타나는 30개 유전자의 돌연변이를 검사하여 치매를 진단할 수 있는 유전자 분석 진단방법에 관한 것이다.
알츠하이머병 (AD), 전두측두엽성 치매 (FTD), 근위축성측삭경화증 (ALS), 프리온 질환 (CJD) 및 파킨슨병 (PD)을 비롯한 많은 신경 퇴행성 질환 (neurodegenerative diseases, ND)은 여러 임상적, 병리적 및 분자적 특징이 공통적으로 나타나는 것으로 보고되었다(Bertram L, et al. The genetic epidemiology of neurodegenerative disease. J Clin Invest 2005;115(6):1449-1457). 신경 퇴행성 질환은 신경 세포의 선택적 손실 및 임상 증상으로 기능적 장애를 갖는 질환으로 정의된다. 의료기술이 발달하면서 평균 수명이 길어짐에 따라 질환은 세계에서 주요 건강 문제가 되고 있다. 이러한 문제를 해결하기 위해 전 임상 단계에서 성공적인 치료를 위한 새로운 진단 방법이 필요하다.
Next generation sequencing (NGS)은 인 비트로(in vitro) 및 인 비보(in vivo) 상에서 쉽게 유전적 서열을 확인할 수 있는 기술로서, 최근 몇 년 동안 유전학 연구는 sequencing 기술의 출현으로 인해 상당한 진보를 보였다. NGS 기술을 통하여 점점 더 많은 수의 유전자를 조사할 수 있게 되었고, 이러한 기술의 발달로 질병 진단과 치료를 위해 유전적 돌연변이 발견이 용이해졌다. 최근 확인된 치매와 연관된 대다수의 유전자는 Aβ42 생성 및 제거에 영향을 주거나 ND 병인에 있어서 중요한 경로에 영향을 주는 것으로 알려졌다(Karch CM, et al. Alzheimer's disease risk genes and mechanisms of disease pathogenesis. Biological psychiatry. 2015;77(1):43-51; Lambert JC, et al. Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease. Nat Genet. 2013; Zhang B, et al. Integrated systems approach identifies genetic nodes and networks in late-onset Alzheimer's disease. Cell. 2013;153:707-720). 하지만 어떠한 돌연변이 유전자가 어떤 질병과 연관성이 있는지 규명되지 않은 부분이 상당히 많다. 특히 다양한 퇴행성 뇌질환의 경우 복잡한 상호연관성을 가지고 있기 때문에(Bertram L, et al. The genetic epidemiology of neurodegenerative disease. J Clin Invest 2005;115(6):1449-1457) 한 가지 유전자로 해당 질병을 진단하거나 치료에 적용하기에 문제점이 있다.
본 명세서 전체에 걸쳐 다수의 논문 및 특허문헌이 참조되고 그 인용이 표시되어 있다. 인용된 논문 및 특허문헌의 개시 내용은 그 전체로서 본 명세서에 참조로 삽입되어 본 발명이 속하는 기술 분야의 수준 및 본 발명의 내용이 보다 명확하게 설명된다.
본 발명자들은 치매 중 가장 높은 비중을 차지하고 하고 있는 알츠하이머를 진단할 수 있는 방법을 찾고자 예의 연구 노력하였다. 그 결과 본 발명자들은 알츠하이머 환자에게서 발견된 알츠하이머 관련 돌연변이 유전자30개를 선별하여 이에 대한 NGS 분석용 프라이머를 디자인 하였고, 이 프라이머를 이용하여 뇌질환 의심 환자들의 대한 돌연변이를 분석함으로써 알츠하이머를 진단할 수 있음을 확인하였다.
따라서, 본 발명의 목적은 알츠하이머 진단을 위한 정보제공방법을 제공하는데 있다.
본 발명의 다른 목적은 알츠하이머 진단 또는 예후 분석용 키트를 제공하는데 있다.
본 발명의 또 목적은 퇴행성 뇌질환 진단을 위한 정보제공방법을 제공하는데 있다.
본 발명의 또 목적은 퇴행성 뇌질환 진단 또는 예후 분석용 키트를 제공하는데 있다.
본 발명의 다른 목적 및 이점은 하기의 발명의 상세한 설명, 청구범위 및 도면에 의해 보다 명확하게 된다.
본 발명의 일 양태에 따르면, 본 발명은 진단하고자 하는 개체로부터 분리된 생물학적 시료의 유전자 돌연변이를 분석하는 단계를 포함하며, 상기 유전자 돌연변이는 APP (amyloid precursor protein), PSEN1 (presenilin), PSEN2 (presenilin 2), CR1 (complement receptor 1), BIN1 (Bridging integrator 1), TREM2 (triggering receptor expressed on myeloid cells 2), CLU (clusterin), CTNNA3 (Cadherin-associated protein alpha 3), DNMBP (Dynamin binding protein), SORL1 (sortilin-related receptor 1), BACE1 (Beta-secretase 1), PICALM (Phosphatidylinositol binding clathrin assembly protein), LPR6 (low-density lipoprotein receptor-related protein 6), ADAM10 (Disintegrin and metalloproteinase domain-containing protein 10), ABCA7 (ATP-binding cassette transporter A7), CD33 (sialic acid binding Ig-like lectin 3), TDP43 (TAR-DNA binding protein-43), SIGMAR1 (sigma non-opioid intracellular receptor 1), FUS (Fused-in-Sarcoma), GRN(PGRN) (progranulin), MAPT (microtubule associated Tau protein), ALS2 (amyotrophic lateral sclerosis), PINK1 (PTEN-induced putative kinase 1), PARK7 (Colony Stimulating Factor 1 Receptor), PARK9 (ATPase 13A2 or PTEN Induced Putative Kinase 1), SNCA (Alpha synuclein), LRRK2 (Leucine-rich repeat kinase 2), CSF1R (colony stimulating factor 1 receptor), NOCTH3 (Neurogenic locus notch homolog protein 3), PRNP (prion protein gene) 및 이의 조합으로 구성된 군에서 선택되는 유전자의 엑손(exon) 부위 돌연변이인, 알츠하이머 진단을 위한 정보제공방법을 제공한다.
본 발명자들은 치매 중 가장 높은 비중을 차지하고 하고 있는 알츠하이머를 진단할 수 있는 방법을 찾고자 예의 연구 노력한 결과, 알츠하이머 환자에게서 발견된 알츠하이머 관련 돌연변이 유전자 30개를 선별하여 이에 대한 NGS 분석용 프라이머를 디자인 하였고, 이 프라이머를 이용하여 여러 뇌질환 의심 환자들의 대한 돌연변이를 분석함으로써 알츠하이머를 진단할 수 있음을 확인하였다.
본 발명에서는 EOAD 환자에서 APP, PSEN1, PSEN2, CR1, BIN1, CLU, CTNNA3, DNMBP, SORL1, BACE1, PICALM, LPR6, ADAM10, ABCA7, CD33, SIGMAR1, FUS, GRN, MAPT, ALS2, PINK1, PARK7, PARK9, SNCA, LRRK2, CSF1R, NOTCH3 및 PRNP 유전자의 돌연변이를 발견하였으며, 특히, PSEN1, CLU, CTNNA3, SORL1, LRP6, ABCA7, PINK1, ATP13A2 (PARK9), LRRK2, FUS, GRN (PGRN), ALS2, CSF1R, NOTCH3 및 PRNP 유전자에서 신규한(novel) 돌연변이가 발견되었다.
또한, LOAD 환자에서도 APP, CR1, BIN1, CLU, CTNNA3, DNMBP, SORL1, BACE1, PICALM, LPR6, ADAM10, ABCA7, CD33, SIGMAR1, MAPT, ALS2, PINK1, PARK9, LRRK2, CSF1R, NOTCH3 및 PRNP 유전자의 돌연변이를 발견하였고, 특히 APP, CLU, ADAM10, ATP13A2 (PARK9), LRRK 및 NOTCH3 유전자의 신규한 돌연변이를 발견하였다.
본 발명의 일 구현예에 따르면, 상기 유전자는 APP, PSEN1, PSEN2, CR1, BIN1, CLU, CTNNA3, DNMBP, SORL1, BACE1, PICALM, LPR6, ADAM10, ABCA7, CD33, SIGMAR1, FUS, GRN, MAPT, ALS2, PINK1, PARK7, PARK9, SNCA, LRRK2, CSF1R, NOTCH3 및 PRNP 및 이의 조합으로 구성된 군에서 선택될 수 있다. 본 발명의 다른 구현예에 따르면, 상기 유전자는 APP, CR1, BIN1, CLU, CTNNA3, DNMBP, SORL1, BACE1, PICALM, LPR6, ADAM10, ABCA7, CD33, SIGMAR1, MAPT, ALS2, PINK1, PARK9, LRRK2, CSF1R, NOTCH3 및 PRNP 및 이의 조합으로 구성된 군에서 선택될 수 있다.
본 발명의 특정 구현예에 따르면, 알츠하이머의 진단에 있어서 상기 30개의 유전자의 돌연변이를 분석하되, 각 유전자에서 1 이상의 돌연변이를 검출할 수 있고, 각 유전자의 돌연변이 검출에 있어서는 1개 이상의 프라이머 세트를 사용할 수 있다. 상기 돌연변이는 하기 실시예의 표 2 및 표 3에 기재되어 있다.
본 발명에서 상기 생물학적 시료는 혈액, 정액, 질 세포, 모발, 타액, 소변, 구강세포, 태반세포 또는 태아세포를 포함하는 양수 및 이의 혼합물로 구성된 군에서 선택되는 시료로부터 분리된 DNA 시료이다. 본 발명의 일 구현예에 따르면, 상기 생물학적 시료는 혈액으로부터 분리된 DNA 시료이다.
상기 DNA 시료는 당업계에 공지된 통상적인 방법을 통해 수득할 수 있다. 예컨대, 상기 조직에 DNA 용해 완충액(예컨대, tris-HCl, EDTA, EGTA, SDS, 디옥시콜레이트(deoxycholate), 및 트리톤X (tritonX) 및/또는 NP-40을 포함)을 처리하여 DNA를 분리한다.
본 발명의 일 구현예에 따르면, DNA 시료는 DNA를 포함하는 생물학적 시료(biological sample)이다.
본 명세서에 기술된 용어 “증폭”은 핵산 분자를 증폭하는 반응을 의미한다. 다양한 증폭 반응들이 당업계에 보고 되어 있으며, 이는 중합효소 연쇄반응(이하 PCR이라 한다)(미국 특허 제4,683,195, 4,683,202, 및 4,800,159호), 역전사-중합효소 연쇄반응(이하 RT-PCR로 표기한다)(Sambrook 등, Molecular Cloning. A Laboratory Manual, 3rd ed. Cold Spring Harbor Press(2001)), Miller, H. I.(WO 89/06700) 및 Davey, C. 등(EP 329,822)의 방법, 리가아제 연쇄 반응(ligase chain reaction; LCR)(17, 18), Gap-LCR(WO 90/01069), 복구 연쇄 반응(repair chain reaction; EP 439,182), 전사-중재 증폭(transcription-mediated amplification; TMA)(19) (WO 88/10315), 자가 유지 염기서열 복제(self sustained sequence replication)(20)(WO 90/06995), 타깃 폴리뉴클레오티드 염기서열의 선택적 증폭(selective amplification of target polynucleotide sequences)(미국 특허 제6,410,276호), 컨센서스 서열 프라이밍 중합효소 연쇄 반응(consensus sequence primed polymerase chain reaction; CP-PCR)(미국 특허 제4,437,975호), 임의적 프라이밍 중합효소 연쇄 반응(arbitrarily primed polymerase chain reaction; AP-PCR)(미국 특허 제5,413,909호 및 제5,861,245호), 핵산 염기서열 기반 증폭(nucleic acid sequence based amplification; NASBA)(미국 특허 제5,130,238호, 제5,409,818호, 제5,554,517호, 및 제6,063,603호), 가닥 치환 증폭(strand displacement amplification) 및 고리-중재 항온성 증폭(loop-mediated isothermal amplification; LAMP)을 포함하나, 이에 한정되지는 않는다. 사용 가능한 다른 증폭 방법들은 미국특허 제5,242,794, 5,494,810, 4,988,617호 및 미국 특허 제09/854,317호에 기술되어 있다.
PCR은 가장 잘 알려진 핵산 증폭 방법으로, 그의 많은 변형과 응용들이 개발되어 있다. 예를 들어, PCR의 특이성 또는 민감성을 증진시키기 위해 전통적인 PCR 절차를 변형시켜 터치다운(touchdown) PCR, 핫 스타트(hot start) PCR, 네스티드(nested) PCR 및 부스터(booster) PCR이 개발되었다. 또한, Emulsion PCR, Polony PCR, 멀티플렉스(multiplex) PCR, 실시간(real-time) PCR, 분별 디스플레이 PCR(differential display PCR, D-PCR), cDNA 말단의 신속 증폭(rapid amplification of cDNA ends, RACE), 인버스 PCR (inverse polymerase chain reaction: IPCR), 벡토레트(vectorette) PCR, 및 TAIL-PCR(thermal asymmetric interlaced PCR)이 특정한 응용을 위해 개발되었다. PCR에 대한 자세한 내용은 McPherson, M.J., 및 Moller, S.G. PCR. BIOS Scientific Publishers, Springer-Verlag New York Berlin Heidelberg, N.Y. (2000)에 기재되어 있으며, 그의 교시사항은 본 명세서에 참조로 삽입된다.
본 발명에서 상기 돌연변이 분석은 상기 유전자에 상보적으로 결합하는 각각의 프라이머를 이용하여 유전자를 증폭하고, 상기 증폭산물의 시퀀싱(sequencing) 데이터를 이용하여 유전자 돌연변이를 분석함으로써 실시할 수 있다. 또는 상기 돌연변이 분석은 RFLP (Restriction frangment length polymorphism) 또는 Allele specific PCR 의 방법을 이용하여 분석할 수도 있다.
본 발명의 일 구현예에 따르면, 상기 시퀀싱은 NGS (next generation sequencing) 방법을 이용하여 실시할 수 있다. 본 발명에서 NGS 데이터세트는 Torrent Suite Software v.4.4.3 (Life Technologies)으로 분석하였으며, 돌연변이 분석은 Integrative Genome Viewer (IGV) software (software.broadinstitute.org/igv/)로 진행하였다.
본 발명에서는 각 유전자에 대한 프라이머를 이용하여 돌연변이 분석을 실시할 수 있으며, 각 유전자별로 한 쌍(pair) 이상의 프라이머 세트를 이용할 수 있다. 본 발명에서 이용한 프라이머는 표 4 내지 표 33에 개시되어 있다.
본 발명의 특정 구현예에 따르면, 본 발명의 방법에서 APP 유전자의 엑손(exon)에 상보적으로 결합하는 프라이머 세트를 1세트 내지 18세트 사용할 수 있고; 상기 PSEN1 유전자에 상보적으로 결합하는 프라이머 세트를 1세트 내지 12세트 사용할 수 있고; 상기 PSEN2 유전자에 상보적으로 결합하는 프라이머 세트를 1세트 내지 13세트 사용할 수 있고; 상기 CR1 유전자에 상보적으로 결합하는 프라이머 세트를 1세트 내지 52세트 사용할 수 있고; 상기 BIN1 유전자에 상보적으로 결합하는 프라이머 세트를 1세트 내지 16세트 사용할 수 있고; 상기 TREM2 유전자에 상보적으로 결합하는 프라이머 세트를 1세트 내지 4세트 사용할 수 있고; 상기 CLU 유전자에 상보적으로 결합하는 프라이머 세트를 1세트 내지 10세트 사용할 수 있고; 상기 CTNNA3 유전자에 상보적으로 결합하는 프라이머 세트를 1세트 내지 19세트 사용할 수 있고; 상기 DNMBP 유전자에 상보적으로 결합하는 프라이머 세트를 1세트 내지 23세트 사용할 수 있고; 상기 SORL1 유전자에 상보적으로 결합하는 프라이머 세트를 1세트 내지 48세트 사용할 수 있고; 상기 BACE1 유전자에 상보적으로 결합하는 프라이머 세트를 1세트 내지 9세트 사용할 수 있고, 상기 PICALM 유전자에 상보적으로 결합하는 프라이머 세트를 1세트 내지 19세트 사용할 수 있고; 상기 LPR6 유전자에 상보적으로 결합하는 프라이머 세트를 1세트 내지 25세트 사용할 수 있고; 상기 ADAM10 유전자에 상보적으로 결합하는 프라이머 세트를 1세트 내지 16세트 사용할 수 있고; 상기 ABCA7 유전자에 상보적으로 결합하는 프라이머 세트를 1세트 내지 47세트 사용할 수 있고; 상기 CD33 유전자에 상보적으로 결합하는 프라이머 세트를 1세트 내지 8세트 사용할 수 있고; 상기 TDP43 유전자에 상보적으로 결합하는 프라이머 세트를 1세트 내지 11세트 사용할 수 있고; 상기 SIGMAR1 유전자에 상보적으로 결합하는 프라이머 세트를 1세트 내지 6세트 사용할 수 있고; 상기 FUS 유전자에 상보적으로 결합하는 프라이머 세트를 1세트 내지 15세트 사용할 수 있고; 상기 GRN 유전자에 상보적으로 결합하는 프라이머 세트를 1세트 내지 13세트 사용할 수 있고; 상기 MAPT 유전자에 상보적으로 결합하는 프라이머 세트를 1세트 내지 15세트 사용할 수 있고; 상기 ALS2 유전자에 상보적으로 결합하는 프라이머 세트를 1세트 내지 39세트 사용할 수 있고; 상기 PINK1 유전자에 상보적으로 결합하는 프라이머 세트를 1세트 내지 9세트 사용할 수 있고; 상기 PARK7 유전자에 상보적으로 결합하는 프라이머 세트를 1세트 내지 7세트 사용할 수 있고; 상기 PARK9 유전자에 상보적으로 결합하는 프라이머 세트를 1세트 내지 28세트 사용할 수 있고; 상기 SNCA 유전자에 상보적으로 프라이머 세트를 1세트 내지 6세트 사용할 수 있고; 상기 LRRK2 유전자에 상보적으로 결합하는 프라이머 세트를 1세트 내지 54세트 사용할 수 있고; 상기 CSF1R 유전자에 상보적으로 결합하는 프라이머 세트를 1세트 내지 22세트 사용할 수 있고; 상기 NOTCH3 유전자에 상보적으로 결합하는 프라이머 세트를 1세트 내지 35세트 사용할 수 있고; 상기 PRNP 유전자에 상보적으로 결합하는 프라이머 세트를 1세트 내지 4세트 사용할 수 있다.
본 발명에서는 유전자 당 1 세트 이상의 프라이머를 사용하여 돌연변이를 검출하는데 사용할 수 있다.
본 발명의 일 구현예에 따르면, 상기 프라이머를 이용한 유전자 증폭을 위하여, 멀티플렉스 PCR(Polymerase Chain Reaction) 증폭방법을 사용할 수 있다. 본 발명의 다른 구현예에 따르면, 상기 멀티플렉스 증폭은 에멀젼(emulsion) 멀티플렉스 PCR 증폭이다.
본 발명의 또 다른 구현예에 따르면, 상기 프라이머를 이용한 유전자 증폭을 위하여, Emulsion PCR, Polony PCR 또는 Bridge PCR 방법을 사용할 수 있다.
본 발명의 다른 양태에 따르면, 본 발명은 APP (amyloid precursor protein), PSEN1 (presenilin), PSEN2 (presenilin 2), CR1 (complement receptor 1), BIN1 (Bridging integrator 1), TREM2 (triggering receptor expressed on myeloid cells 2), CLU (clusterin), CTNNA3 (Cadherin-associated protein alpha 3), DNMBP (Dynamin binding protein), SORL1 (sortilin-related receptor 1), BACE1 (Beta-secretase 1), PICALM (Phosphatidylinositol binding clathrin assembly protein), LPR6 (low-density lipoprotein receptor-related protein 6), ADAM10 (Disintegrin and metalloproteinase domain-containing protein 10), ABCA7 (ATP-binding cassette transporter A7), CD33 (sialic acid binding Ig-like lectin 3), TDP43 (TAR-DNA binding protein-43), SIGMAR1 (sigma non-opioid intracellular receptor 1), FUS (Fused-in-Sarcoma), GRN(PGRN) (progranulin), MAPT (microtubule associated Tau protein), ALS2 (amyotrophic lateral sclerosis), PINK1 (PTEN-induced putative kinase 1), PARK7 (Colony Stimulating Factor 1 Receptor), PARK9 (ATPase 13A2 or PTEN Induced Putative Kinase 1), SNCA (Alpha synuclein), LRRK2 (Leucine-rich repeat kinase 2), CSF1R (colony stimulating factor 1 receptor), NOCTH3 (Neurogenic locus notch homolog protein 3), PRNP (prion protein gene) 및 이의 조합으로 구성된 군에서 선택되는 유전자의 엑손(exon) 부위에 상보적으로 결합하는 각각의 프라이머를 이용하여 유전자 돌연변이를 분석하는 알츠하이머 진단 또는 예후 분석 키트를 제공한다.
본 발명의 알츠하이머 진단 또는 예후 분석 키트는 상술한 “알츠하이머 진단을 위한 정보제공방법”을 이용하기 때문에, 공통된 사항은 본 명세서의 과도한 중복성을 피하기 위해 그 기재를 생략한다.
본 발명의 또 다른 양태에 따르면, 본 발명은 진단하고자 하는 개체로부터 분리된 생물학적 시료의 유전자 돌연변이를 분석하는 단계를 포함하며, 상기 유전자 돌연변이는 APP (amyloid precursor protein), PSEN1 (presenilin), PSEN2 (presenilin 2), CR1 (complement receptor 1), BIN1 (Bridging integrator 1), TREM2 (triggering receptor expressed on myeloid cells 2), CLU (clusterin), CTNNA3 (Cadherin-associated protein alpha 3), DNMBP (Dynamin binding protein), SORL1 (sortilin-related receptor 1), BACE1 (Beta-secretase 1), PICALM (Phosphatidylinositol binding clathrin assembly protein), LPR6 (low-density lipoprotein receptor-related protein 6), ADAM10 (Disintegrin and metalloproteinase domain-containing protein 10), ABCA7 (ATP-binding cassette transporter A7), CD33 (sialic acid binding Ig-like lectin 3), TDP43 (TAR-DNA binding protein-43), SIGMAR1 (sigma non-opioid intracellular receptor 1), FUS (Fused-in-Sarcoma), GRN(PGRN) (progranulin), MAPT (microtubule associated Tau protein), ALS2 (amyotrophic lateral sclerosis), PINK1 (PTEN-induced putative kinase 1), PARK7 (Colony Stimulating Factor 1 Receptor), PARK9 (ATPase 13A2 or PTEN Induced Putative Kinase 1), SNCA (Alpha synuclein), LRRK2 (Leucine-rich repeat kinase 2), CSF1R (colony stimulating factor 1 receptor), NOCTH3 (Neurogenic locus notch homolog protein 3), PRNP (prion protein gene) 및 이의 조합으로 구성된 군에서 선택되는 유전자의 엑손(exon) 부위 돌연변이인, 신경 퇴행성 질환(neurodegenerative disease) 진단을 위한 정보제공방법을 제공한다.
본 발명의 또 다른 양태에 따르면, 본 발명은 APP (amyloid precursor protein), PSEN1 (presenilin), PSEN2 (presenilin 2), CR1 (complement receptor 1), BIN1 (Bridging integrator 1), TREM2 (triggering receptor expressed on myeloid cells 2), CLU (clusterin), CTNNA3 (Cadherin-associated protein alpha 3), DNMBP (Dynamin binding protein), SORL1 (sortilin-related receptor 1), BACE1 (Beta-secretase 1), PICALM (Phosphatidylinositol binding clathrin assembly protein), LPR6 (low-density lipoprotein receptor-related protein 6), ADAM10 (Disintegrin and metalloproteinase domain-containing protein 10), ABCA7 (ATP-binding cassette transporter A7), CD33 (sialic acid binding Ig-like lectin 3), TDP43 (TAR-DNA binding protein-43), SIGMAR1 (sigma non-opioid intracellular receptor 1), FUS (Fused-in-Sarcoma), GRN(PGRN) (progranulin), MAPT (microtubule associated Tau protein), ALS2 (amyotrophic lateral sclerosis), PINK1 (PTEN-induced putative kinase 1), PARK7 (Colony Stimulating Factor 1 Receptor), PARK9 (ATPase 13A2 or PTEN Induced Putative Kinase 1), SNCA (Alpha synuclein), LRRK2 (Leucine-rich repeat kinase 2), CSF1R (colony stimulating factor 1 receptor), NOCTH3 (Neurogenic locus notch homolog protein 3), PRNP (prion protein gene) 및 이의 조합으로 구성된 군에서 선택되는 유전자의 엑손(exon) 부위에 상보적으로 결합하는 각각의 프라이머를 이용하여 유전자 돌연변이를 분석하는 신경 퇴행성 질환(neurodegenerative disease) 진단 또는 예후 분석 키트를 제공한다.
본 발명에서 신경 퇴행성 질환은 알츠하이머병(Alzheimer's disease), 루게릭병(Amyotrophic Lateral Sclerosis), 전두측두엽성 치매(Frontotemporal dementia), 루이소체 치매(Dementia with Lewy Bodies), 크루츠펠트 야콥병 (Creutzfeldt Jakob Disease), 파킨슨병(Parkinson’s disease), 뇌졸중(stroke), 근위축성측색경화증(amyotrophic lateral sclerosis), 빈스완거병(Binswanger’s disease), 헌팅톤 무도병(Huntington’s chorea), 다발성 경화증(multiple sclerosis), 중증 근무력증(myasthenia gravis) 및 피크병(Pick’s disease)을 포함하며 이에 한정되는 것은 아니다.
상기 신경 퇴행성 질환과 관련된 유전자는 하기 실시예 표 1에 개시되어 있다.
본 발명의 특징 및 이점을 요약하면 다음과 같다:
(a) 본 발명은 알츠하이머 진단을 위한 정보제공방법 및 이를 이용한 진단키트에 관한 것이다.
(b) 본 발명의 방법을 이용한 유전자 돌연변이 분석결과에 따라 알츠하이머병 환자에게 개인적 맞춤 진단 및 치료가 가능할 것으로 기대된다.
(c) 본 발명의 방법을 이용하여 알츠하이머와 연관된 30개의 유전자를 스크리닝하여 환자가 가지고 있는 유전적 문제점을 확인 후 개별 맞춤 치료를 적용할 수 있다. 국내에서 알츠하이머 환자에게 다양한 유전자 검사를 적용하여 치료에 활용하는 경우는 없으므로 본 발병은 알츠하이머 진단에 있어 충분한 경쟁력이 있을 것으로 예상된다.
도 1은 염색체 상의 30개 후보 유전자 위치를 나타낸다.
도 2는 PCR 매개 유전자 스플라이싱 전략을 나타내는 모식도이다.
이하, 실시예를 통하여 본 발명을 더욱 상세히 설명하고자 한다. 이들 실시예는 오로지 본 발명을 보다 구체적으로 설명하기 위한 것으로, 본 발명의 요지에 따라 본 발명의 범위가 이들 실시예에 의해 제한되지 않는다는 것은 당업계에서 통상의 지식을 가진 자에 있어서 자명할 것이다.
실시예
실험 방법
1. 프라이머 디자인
Primer3Plus (www.primer3plus.com) 소프트웨어를 활용하여 해당 유전자에 가장 적합한 프라이머를 디자인하였다(하기 표 4 내지 표 33 참조). 유전자의 full-length를 전부 PCR로 증폭하여 샘플을 준비하는 과정이 어렵기 때문에 각 엑손(exon)마다 프라이머를 만들어 진행하였다. 그리고 겹치는 부분이 있기 때문에 최종적으로 full-length DNA를 만들 수 있다(도 2 참조). 도 3은 실험의 전반적인 흐름을 도식화하여 나타낸 것이다.
2. 차세대 염기서열분석 (next generation sequencing, NGS)
Ion Torrent PGM system을 이용하여 NGS를 실행하였다. 20 ng DNA를 이용하여 멀티플렉스 PCR 을 수행하였다(Ion AmpliSeq Customized Panel, Life Technologies, Grand Island, NY, USA). 단편 라이브러리는 DNA 단편화, 바코드 및 어댑터 결합 및 Ion DNA Barcoding 키트 (Life Technologies, Grand Island, NY, USA)를 이용한 라이브러리 증폭에 의해 구축되었다. DNA 단편의 크기 분포를 High Sensitivity Kit (Agilent, Santa Clara, CA, USA)를 사용하여 Agilent Bioanalyzer로 분석하였다. 주형 제작, 에멀젼(emulsion) PCR 및 이온 구형 입자 (ISP) 농축은 제조사의 지침에 따라 Ion Xpress Template kit (Life Technologies, Grand Island, NY, USA)를 사용하여 수행하였다. ISP를 P1 칩에 로딩하고 이온 P1 시퀀싱 200 키트 (Life Technologies, Grand Island, NY, USA)를 사용하여 시퀀싱하였다. NGS에서 나온 결과는 Torrent Suite Software v.4.4.3 (Life Technologies)으로 분석하였으며, 돌연변이 분석은 Integrative Genome Viewer (IGV) software (software.broadinstitute.org/igv/)로 진행하였다.
선행 연구결과나 다른 논문에서 보고된 결과, 또는 Alzforum에 있는 정보를 토대로 30개 유전자를 선정하였다(하기 표 1 참조). 선정된 30개의 유전자에 대해 디자인된 프라이머를 사용하여 NGS 데이터를 얻었다. 선정된 30개의 유전자는 퇴행성 뇌질환을 분석 및 치료 목적으로 활용하였다. 표 2 및 표 3은 디자인된 프라이머로 66명의 EOAD (Early Onset Alzheimer's Disease) 환자와 26명의 LOAD (Late Onset Alzheimer's Disease) 포함 치매환자에게서 30개 유전자에 대한 돌연변이를 분석한 결과이다. 이와 같이 본 발명의 프라이머를 이용하여 여러 뇌질환 의심 환자들의 대한 돌연변이를 분석할 수 있다. 본 발명의 방법에 의한 돌연변이 분석 결과를 다른 진단 기술과 접목하여 진단의 정확도를 높일 수 있으며, 해당 돌연변이에 의한 생물학적 문제가 생길 것으로 예측하여, 이와 관련된 치료에 접근할 수 있다.
실험결과
디자인된 프라이머를 사용하여 초기 발병 알츠하이머 환자 (EOAD, Early onset Alzheimer’s disease)와 후발성 알츠하이머 환자 (LOAD, late onset Alzheimer’s disease)의 혈액에서 DNA를 추출하여 돌연변이를 분석하였다. 66명의 EOAD 환자와 26명의 LOAD포함 치매환자에게서 30개 유전자에 대한 돌연변이를 분석한 결과를 정리하여 표 2에 나타내었다. 도 1은 선별된 유전자들이 위치한 염색체를 보여주며, 선별된 유전자와 유전자들이 연관된 질병을 표 1에 나타내었다. 표 1에 기대된 30개의 유전자는 기존 선행연구와 다른 선행문헌을 통해 선별된 유전자이다.
30 개 후보유전자 및 관련 질병
관련 질병 유전자수 후보 유전자 선정
Alzheimer's disease (AD) 16 APP, PSEN1 , PSEN2 , CR1, BIN1 , TREM2 , CLU , CTNNA3, DNMBP , SORL1 , BACE1 , PICALM , LPR6 , ADAM10, ABCA7 , CD33.
ALS (Amyotrophic Lateral Sclerosis) & FTD (Frontotemporal dementia) 6 TDP43 , SIGMAR1 , FUS , GRN , MAPT , ALS2
PD (Dementia with Lewy Bodies) 5 PINK1 , PARK7 , PARK9 , SNCA , LRRK2
기타 퇴행성 질환 3 CSF1R , NOTCH3 , PRNP
Ion AmpliSeq™ NGS Panel 을 이용하여 66 명 EOAD 환자를 분석한 결과 (T means tolerated, D means damaging)
Genes DNA change Protein change Mutation frequency rs ID PolyPhen2 HumDiv Sift score Clinical features
PSEN1 c.356C>T (Exon 5) p.T119I 1/66 Novel 0.9 (D) 0.06 (T) Novel mutation
c.626G>C (Exon 7) p.G209A 1/66 Novel 1 (D) 0 (D) Novel mutation
c.695T>C (Exon 7) p.L232P 1/66 Novel 1 (D) 0 (D) Novel mutation
c.1250G>C (Exon 12) p.G417A 1/66 Novel 0.99 (D) 0 (D) Novel mutation
PSEN2 c.505C>A (Exon 6) p.H169N 1/66 0.0001648 0.925 (D) 0.04 (D) Known mutation, pathogenic nature unclear
TREM2 No mutation
CR1 c.394A>C p.T132P 1/66 rs55906048 0.07 (B) 0.345 (T) Probable benign variant
c.4973A>G p.H1658R 16/66 rs2274567 0.98 (D) 0.89 (T) Possible risk factor for AD
c.5573C>T p.T1858M 32/100 rs3737002 0.995 (D) 0.019 (D) Common variant, possible AD risk factor
c.6178A>T p.T2060S 66/66 rs4844609 0.95 (D) 0.019 (D) Common variant, possible AD risk factor
c.6193A>G p.I2065V 18/66 rs6691117 0.005 (B) 1 (T) Common variant, possible AD risk factor
c.6653T>C p.V2218A 1/66 rs191751915 0.85 (D) 0.19 (T) Possible AD risk factor
c.6830C>G p.P2277R 18/66 rs3811381 0.032 (B) 0.44 (T) Probable benign variant
c.7255A>G p.T2419A 29/66 rs2296160 0.001 (B) 0.98 (T) Common variant
BIN1 c.1292C>T p.P431L 4/66 rs141119288 0.99 (D) 0.07 (T) Probably AD risk factor
CLU c.380G>A p.R127H 1/66 Novel 0.56 (D) 0.003 (D) Probably AD risk factor
CTNNA3 c.1787G>A p.S596N 14/66 rs4548513 0.001 (B) 1 (T) Possible risk factor for LOAD and autism
c.1850T>C p.I617T 2/66 Novel 0.928 (D) 0.001 (D) Unknown significance
c.2404G>T p.D802Y 1/66 Novel 0.99 (D) 0.001 (D) Unknown significance
DNMBP c.2633C>T p.A878V 1/66 rs116707029 0.67 (D) 0.035 (D) Unknown significance
c.3154C>T p.R1052W 1/66 rs115117818 1 (D) 0.001 (D) Unknown significance
c.3410G>A p.R1137Q 1/66 rs116296676 0.99 (D) 0.006 (T) Unknown significance
c.4239T>G p.C1413W 28/66 rs11190305 0.094 (B) 0.18 (T) Common variant
SORL1 c.829G>C p.V277L 1/66 Novel 0.173 (B) 0.01 (D) Unknown significance
c.1528G>C p.G511R 1/66 Novel 0.99 (D) 0 (D) Unknown significance
c.1582G>A p.A528T 22/66 rs2298813 0.59 (D) 0.3 (T) AD risk factor
c.2586T>G p.D862E 1/66 Novel 0.178 (B) 0.05 (D) Unknown
:c.3220C>G p.E1074Q 66/66 rs1699107 0 (B) 0.16 (T) Common variant
c.3476G>A p.R1159Q 1/66 rs527617199 0.62 (D) 0.45 (T) Unknown
:c.4447A>G p.T1483A 1/66 rs143286467 0.002 (D) 0.3 (T) Unknown
c.4570G>A p.G1524R 2/66 rs201415809 0.99 (D) 0.005 (D) Unknown
c.5899A>G p.V1967I 66/66 rs1792120 0.003 (B) 1 (T) Common, unknown
c.6289G>A p.V2097I 1/66 rs74642146 0.9 (D) 0.16 (T) Unknown
BACE1 c.1141C>T p.C481R 66/66 rs539765 0 (B) 0.4 (T) Common mutation
LRP6 c.379T>A p.S127T 2/66 rs17848270 0.001 (B) 0.8 (T) Unknown
c.427A>G p.I143V 1/66 Novel 0.93 (D) 0.13 (T) Unknown
c.2902C>T p.R968W 1/66 Novel 0.99 (D) 0.001 (D) Unknown
c.3184G>A p.V1062I 59/66 rs2302685 0 (B) 1 (T) Common mutation, possible AD risk factor
ADAM10 c.763A>G p.T255A 2/66 rs147572059 0.004 (B 0.88 (T) Unknown
ABCA7 c.563A>G p.E188G 9/66 rs3764645 0.06 (B) 0.67 (T) Unknown
c.955A>G p.T319A 11/66 rs3752232 0.142 (B) 0.446 (T) Possible AD risk factor
c.1184A>G p.H395R 11/66 rs3764647 0.02 (B 1 (T) Possible AD risk factor
c.1384G>C p.V462L 1/66 Novel 0.08 (B) 0.086 (T) Unknown
c.1388G>A p.R463H 3/66 rs3752233 0.8 (D) 0.25 (T) Unknown
c.2153A>C p.N718T 3/66 rs3752239 0.58 (D) 0.24 (T) Unknown
c.1620delC p.D540fs 1/66 Novel - - Unknown
c.1832T>G p.V611G 1/66 Novel 0.97 (D) 0.004 (D) Unknown
c.2892C>G p.D964E 2/66 rs117390715 1 (D) 0 (D) Unknown
c.2923C>T p.R975C 1/66 Novel 1 (D) 0 (D) Unknown
c.3629G>A p.R1210Q 1/66 Novel 0.006 (B) 1 (T) Unknown
c.3641G>A p.W1214* 1/66 Known - - AD risk factor, stop codon
c.4046G>A p.R1349Q 6/66 rs3745842 0.004 (B) 0.54 (T) Common variant, unknown
c.4211A>G p.K1404R 1/66 Novel 0.03 (B) 0.002 (D) Unknown
c.4580G>C p.G1527A 29/66 rs3752246 0 (B) 0.87 (T) Common variant, unknown
c.5057A>G p.Q1686R 3/66 rs4147918 0.004 (B) 0.23 (T) Common variant, unknown
c.5069T>C p.I1690T 2/66 rs184218896 0.911 (D) 0.001 (T) Unknown
c.5666C>T p.P1898S 1/66 Novel 0.9 (D) 0.08 (T) Unknown
c.5789A>G p.N1930S 1/66 Novel 0.98 (D) 0.002 (D) Unknown
c.5963G>T p.C1988F 1/66 rs142573667 1 (D) 0 (D) Unknown
c.6133G>T p.A2045S 11/66 rs4147934 0.051 (B) 0.96 (T) Common mutation, unknown
c.6633G>T p.F2071C 2/66 Novel 0.5 (B) 0.46 (T) Common mutation, unknown
CD33 c.41C>T p.A14V 1/66 rs12459419 0.023 (B) 0.08 (T) AD risk factor
c.205A>G p.R69G 3/66 rs2455069 0.009 (B) 0.33 (T) Unknown
c.594A>G p.I198M 1/66 rs200827254 0.105 (B) 0.006 (T) Unknown
c.880G>T p.V294L 1/66 rs2271652 0.001 (B) 0.16 (T) Unknown
PINK1 c.755A>T p.E252V 1/66 Novel 0.605 (D) 0.05 (D) unknown
c.1018G>A p.A340T 35/66 rs3738136 0.001 (B) 1 (T) Unknown
c.1562A>C p.N521T 33/66 rs1043424 0.005 (B) 0.24 (T) Unknown
PARK7 c.535G>A p.A179T 1/66 rs71653622 0. 001 (B) 0.56 (T) Unknown
ATP13A2 (PARK9) c.317A>G p.Q106R 1/66 Novel 0.008 (B) 0.47 (T) Unknown
c.1817C>G p.P606R 1/66 Novel 0.93 (D) 0.025 (D) Unknown
c.3175C>T p.L1059F 1/66 Novel 0.74 (D) 0.005 (D) Unknown
SNCA c.381G>A p.M127I 1/66 rs191055637 0.77 (D) 0.16 (T) Unknown
PARK2 c.500G>A p.S167N 16/66 rs1801474 0.03 (B) 0.31 (T) Benign variant
c.799T>C p.Y267H 1/66 rs114696251 0.99 (D) 0 (D) Unknown
c.1138G>C p.V380L 4/66 rs1801582 0 (B) 0.37 (T) Benign variant
LRRK2 c.149A>G p.R50H 66/66 rs2256408 0 (B) 1 (T) Common variant, PD risk factor
c.691T>C p.S231P 1/66 rs201332859 0.004 (B) 0.3 (T) Unknown
c.1256C>T p.A419V 2/66 rs34594498 0.49 (D) 0.03 (D) PD risk factor
c.1598T>C p.V533A 1/66 Novel 0.5 (T) 0.004 (D) Unknown
c.1653C>G p.N551K 16/66 rs7308720 0.005 (D) 0.972 (D) Possible PD risk factor
c.2167A>G p.I723V 2/66 rs10878307 0.001 (B) 0.68 (T) Possible PD risk factor
c.4193G>A p.R1398H 13/66 rs7133914 0.58 (D) 0.1 (T) Possible PD risk factor
c.4337C>T p.P1446L 1/66 rs74681492 1 (D) 0.008 (T) Possible risk factor
c.4939T>A, p.S1647T 30/66 rs11564148 0 (B) 0.95 (T) Possible risk factor
c.7153G>A p.G2385R 5/66 rs34778348 0.013(B) 0.4 (T) Possible PD risk factor
c.7190T>C p.M2397T 43/66 rs3761863 0 (B) 0.466 (T) Possible PD risk factor
SIGMAR1 c.5A>C p.Q2P 11/66 rs1800866 0 (B) 0.343 (T) Possible risk factor
c.622C>T p.R208W 6/66 rs11559048 0.94 (D) 0.01 (D) Unknown
c.632G>A p.R211Q 1/66 rs192644838 0.57 (D) 0.29 (T) Unknown
FUS c.451C>T p.P151S 1/66 Novel 0.007 (B) 0.03 (D) Unknown
GRN (PGRN) c.119G>A p.S40N 1/66 Novel 0.75 (D) 0.015 (D) Probable novel mutation
c.1690C>T p.R564C 1/66 Novel 0.87 (D) 0.04 (D) AD risk factor mutation
MAPT c.418C>T p.P140S 3/66 rs151115928 0.846 (D) 0.04 (D) Unknown
c.1321T>C p.Y441H 59/66 rs112757188 0 (B) 0.97 (T) Common mutation, unknown
TDP43 No mutation-
ALS2 c.475G>A p.E159K 2/66 Novel 0.156 (B) 0.15 (T) Unknown
c.1102G>A p.V368M 66/66 Novel 0.009 (B) 0.191 (T) Common mutation, unknown
c.2278C>G p.L760V 1/66 Novel 0.99 (D) 0.14 (T) Unknown
c.2953C>T p.L985F 1/66 rs41308836 0.0953 (D) 0.005 (D) Unknown
c.3517G>A p.E1173K 3/66 rs41309046 0.8 (D) 0.003 (D) Unknown
c.4892A>G p.Y1631C 1/66 Novel 0.003 (D) 0.18 (T) Unknown
CSF1R c.544G>T p.G182C 1/66 Novel 0.782 (D) 0.01 (D) Unknown
c.635T>A p.L212Q 1/66 Novel 0.2 (D) 0.14 (T) Possible novel variant
c.637G>A p.V213M 1/66 Novel 0.93 (D) 0.001 (D) Unknown
c.835G>A p.V279M 3/66 rs3829986 0.19 (B) 0.11 (T) Unknown
c.1085A>G p.H362R 40/66 rs10079250 0.15 (B) 0.06 (T) Common mutation, possible cancer risk factor
c.2806G>A p.G936S 1/66 Novel 0.78 (D) 0.01 (D) Possible novel variant
NOTCH3 c.709G>A p.V237M 1/66 rs2285981 0.25 (B) 0.001 (D) Unknown
c.2320C>G p.P774A 1/66 Novel 0.99 (D) 0.004 (T) Unknown
c.2519G>A p.G840E 1/66 Novel 1 (D) 0.001 (D) Unknown
c.3523C>T p.R1175W 1/66 rs200504060 0.91 (D) 0.004 (D) Unknown
c.3620A>G p.N1207S 2/66 rs141418355 0.99 (D) 0.002 (D) Unknown
c.4348G>A p.A1450T 3/66 Novel 0.61 (D) 0.11 (T) Unknown
c.6668C>T p.A2223V 18/66 rs1044009 0.003 (B) 0.14 (T) Common mutation
PRNP c.385A>G p.M129V 1/66 rs1799990 0.012 (B) 0.024 (D) Pathogenic nature complicated
c.655G>A p.E219K 7/66 rs1800014 0.003 (B) 0.035 (D) Pathogenic nature complicated
c.674A>G p.Y225C 1/66 Novel 0.98 (D) 0.001 (D) May be involved in CJD, novel
c.695T>G p.M232R 1/66 rs74315409 0.707 (D) 0.001 (D) CJD or AD involvement
Ion AmpliSeq™ NGS Panel을 이용하여 26 명 환자 (LOAD + Unknown + dementia)에서 30개 유전자를 분석한 결과 (T means tolerated, D means damaging)
Genes DNA change Protein change Mutation frequency ExAC frequency PolyPhen2 HumDiv Sift score Clinical features
APP c.674T>C p.V225A 1/26 Novel 0.577 (D) 0.496 (T) Unknown significance
PSEN1 No mutation
PSEN2 No mutation
TREM2 No mutation
CR1 c.5573C>T p.1858M 17/26 0.2750 0.995(D) 0.019 (D) Common variant, possible AD risk factor
c.6193A>G p.I2065V 5/26 0.3341 0.005(B) 1 (T) Common variant, possible AD risk factor
c.6178A>T p.T2060S 26/26 0.9853 0.95(D) 0.019(D) Common variant, possible AD risk factor
c.7255A>G p.T2419A 24/26 0.8159 0.001(B) 0.98(T) Common variant
c.6830C>G p.P2277R 4/26 0.2403 0.032(B) 0.44(T) Probable benign variant
BIN1 c.1292C>T p.P431L 1/26 0.003413 0.99(D) 0.07(T) Probably AD risk factor
CLU c.545G>A p.R182H 1/26 Novel 0.87(D) 0.1(T) Probably AD risk factor
c.1283C>G p.P428R 1/26 Novel 1(D) 0.001(D) Probably AD risk factor
CTNNA3 c.1787G>A p.S596N 17/26 0.4120 0.001 (B) 1.0 (T) Common variant
DNMBP c.1119C>G p.N373K 1/26 0.04518 0.016 (B) 0.195 (T) Unknown significance
c.4138G>A p.G1380S 1/26 0.0006599 0.002 (B) 0.94 (T) Unknown significance
c.4239T>G p.C1413W 4/26 0.3442 0.094 (B) 0.18 (T) Common variant
SORL1 c.1582G>A p.A528T 10/26 0.07219 0.59 (D) 0.3 (T) AD risk factor
c.3220C>G p.E1074Q 26/26 0.9949 0 (B) 0.16 (T) Common variant
c.4570G>A p.G1524R 1/26 0.0001813 0.99(D) 0.005(D) Unknown
c.5899A>G p.V1967I 26/26 0.9953 0.003(B) 1(T) Common, unknown
BACE1 c.1141C>T p.C481R 26/26 0.9997 0(B) 0.4 (T) Common mutation
LRP6 c.379T>A p.S127T 1/26 0.001980 0.001(B) 0.8(T) Unknown
c.3184G>A p.V1062I 26/26 0.8474 0(B) 1(T) Common mutation, possible AD risk factor
ADAM10 c.1661A>G p.D554G 1/26 Novel 0.02 (B) 0.377 (T) Unknown
ABCA7 c.563A>G p.E188G 21/26 0.4838 0.06 (B) 0.67 (T) Unknown
c.955A>G p.T319A 4/26 0.06039 0.142 (B) 0.446 (T) Possible AD risk factor
c.1184A>G p.H395R 4/26 0.06298 0.02 (B 1 (T) Possible AD risk factor
c.1388G>A p.R463H 8/26 0.04775 0.8 (D) 0.25 (T) Unknown
c.1570C>T p.R524W 2/26 0.0002259 0.75 (D) 0.01 (D) Unknown
c.2153A>C p.N718T 9/26 0.07028 0.58 (D) 0.24 (T) Unknown
c.4046G>A p.R1349Q 17/26 0.4433 0.004 (B) 0.54 (T) Common variant, unknown
c.4580G>C p.G1527A 24/26 0.8405 0 (B) 0.87(T) Common variant, unknown
c.5057A>G p.Q1686R 8/26 0.04785 0.004(B) 0.23 (T) Common variant, unknown
c.5609G>T p.G1870V 1/26 0.000008395 0.99 (D) 0 (D) Unknown
c.6133G>T p.A2045S 24/26 0.7317 0.051 (B) 0.96 (T) Common mutation, unknown
CD33 c.41C>T p.A14V 11/26 0.2939 0.023 (B) 0.08 (T) AD risk factor
c.205A>G p.R69G 3/26 0.3577 0.009 (B) 0.33 (T) Unknown
PINK1 c.1018G>A p.A340T 10/26 0.09211 0.001(B) 1 (T) Unknown
c.1562A>C p.N521T 14/26 0.09211 0.005 (B) 0.24 (T) Unknown
PARK7 No mutation
ATP13A2 (PARK9) c.1499G>T p.R500L 1/26 Novel 1 (D) 0 (D) Unknown
c.745G>A p.A249T 1/26 0.0001173 0.006(B) 0.25 (T) Unknown
SNCA No mutation
PARK2 c.500G>A p.S167N 20/26 0.06758 0.03(B) 0.31 Benign variant
c.1138G>C p.V380L 4/26 0.1646 0 (B) 0.37 (T) Benign variant
LRRK2 c.149A>G p.R50H 26/26 0.9911 0 (B) 1 (T) Common variant, PD risk factor
c.1653C>G p.N551K 7/26 0.08607 0.005(D) 0.972 (D) Possible PD risk factor
c.2264C>T p.P755L 1/66 Novel 0.2 (B) 0.3 (T) PD risk factor
c.4193G>A p.R1398H 7/26 0.08412 0.58 (D) 0.1(T) Possible PD risk factor
c.4337C>T p.P1446L 1/26 0.0002473 1 (D) 0.008 (T) Possible risk factor
c.4939T>A p.S1647T 14/26 0.2983 0 (B) 0.95 (T) Possible risk factor
c.7153G>A p.G2385R 3/26 0.1129 0.013(B) 0.4 (T) Possible PD risk factor
c.7190T>C p.M2397T 19/26 0.6240 0 (B) 0.466(T) Possible PD risk factor
SIGMAR1 c.5A>C p.Q2P 16/26 0.1840 0 (B) 0.343(T) Possible risk factor
c.632G>A p.R211Q 1/26 0.00009934 0.57 (D) 0.29 (T) Unknown
c.622C>T p.R208W 3/26 0.007782 0.94 (D) 0.01(D) Unknown
FUS No mutation
GRN No mutation
MAPT c.530A>T p.D177V 2/26 0.0007273 0.846 (D) 0.04 (D) Possible involvement with FTD
c.1321T>C p.Y441H 18/26 0.0001799 0.92 (D) 0 (D) Unknown
TDP43 No mutation
ALS2 c.1102G>A p.V368M 26/26 0.9106 0.009(B) 0.191(T) Common mutation, unknown
c.3517G>A p.E1173K 1/26 0.002211 0.8 (D) 0.003(D) Unknown
CSF1R c.835G>A p.V279M 3/26 0.002537 0.19(B) 0.11(T) Unknown
c.1085A>G p.H362R 16/26 0.00009984 0.15 (B) 0.06 (T) Common mutation, possible cancer risk factor
c.733G>T p.A245T 1/26 0.00005022 0.008(B) 0.6(T) Unknown
NOTCH3 c.224G>A p.R75Q 1/26 0.0004639 0.6(D) 0.25(T) Unknown
c.709G>A p.V237M 1/26 0.000008449 0.25(B) 0.001(D) Unknown
c.2208C>A p.D736E 1/26 Novel 0.97(D) 0.004(T) Unknown
c.2966T>G p.L989R 1/26 Novel 0.001(B) 0.06 (T) Unknown
c.6668C>T p.A2223V 23/26 0.7591 0.003(B) 0.14(T) Common mutation
PRNP c.385A>G p.M129V 1/26 0.3078 0.012 (B) 0.024 (D) Pathogenic nature complicated
c.655G>A p.E219K 2/26 0.008728 0.003 (B) 0.035 (D) Pathogenic nature complicated
본 발명에서 디자인된 프라이머 (PSEN2)
Primer ID 서열 Tm (oC) GC (%) 길이 (bp)
XM_005273198.1_ex1F cccagtggacgagggaac 61 66 122
XM_005273198.1_ex1R gctccagcggagtttacg 59 61 122
XM_005273198.1_ex2F tctgttagcagcggtgtttg 60 50 265
XM_005273198.1_ex2R taaacaggggtgaggtctgc 60 55 265
XM_005273198.1_ex3F cagggggaggaaggtgag 61 67 366
XM_005273198.1_ex3R aaaatgccacagcaaactcc 60 45 366
XM_005273198.1_ex4F tgtgtccaagtctccaggtc 59 55 350
XM_005273198.1_ex4R atcagggaatgaatgtctgg 60 48 350
XM_005273198.1_ex5F caaacttctcatttctggttcc 58 41 395
XM_005273198.1_ex5R agtgaccaacacaggctgct 61 55 395
XM_005273198.1_ex6F ccctagcaggtccagaatca 60 55 316
XM_005273198.1_ex6R tctaaaggcggctgtttcac 60 50 316
XM_005273198.1_ex7F gacaccttgtgatcgtgcaa 60 50 213
XM_005273198.1_ex7R gaagactggagctcgatggt 59 55 213
XM_005273198.1_ex8F ttgggactgaatggtggtaa 59 45 398
XM_005273198.1_ex8R caagcccttcagcacctg 61 61 398
XM_005273198.1_ex9F cggggatagtttgacaagga 60 50 173
XM_005273198.1_ex9R accccgagtcaggcagag 61 66 173
XM_005273198.1_ex10F ttctgggacgcagactgg 61 61 272
XM_005273198.1_ex10R actcatgcctctcagggaag 59 55 272
XM_005273198.1_ex11F cactctgaccagctgttgtttc 60 50 282
XM_005273198.1_ex11R cctcatgccctcctccac 62 67 282
XM_005273198.1_ex12F attctgtgcacgcctcttca 62 50 203
XM_005273198.1_ex12R accacgaggcagctggac 62 66 203
XM_005273198.1_ex13F ctcacagctcctgtccacac 59 60 236
XM_005273198.1_ex13R cctgtggcacaccatgtc 59 61 236
본 발명에서 디자인된 프라이머 (CR1)
Primer ID 서열 Tm (oC) GC (%) 길이 (bp)
NM_000573.3_ex1F atgtgcttggggagaatggg 61 55 212
NM_000573.3_ex1R gctgcacgcgagttctct 60 61 212
NM_000573.3_ex2F tggtcttgatctccaggtca 60 50 221
NM_000573.3_ex2R gggttcccactccagagttac 60 57 221
NM_000573.3_ex3F accatcagaactgcgtgtgt 60 50 234
NM_000573.3_ex3R tcaagagatgccaactcaccc 60 52 234
NM_000573.3_ex4F ggtagttgacctgtgtct 59 50 254
NM_000573.3_ex4R tcttcagccgtgtgaaggac 60 55 254
NM_000573.3_ex5_1F cctgctcttcctttttccagg 58 52 260
NM_000573.3_ex5_1R catttggaggcgtgcatttg 61 50 260
NM_000573.3_ex5_2F ccgcccctcagtgcattata 61 55 262
NM_000573.3_ex5_2R tgatccaacagcaacgcatg 61 50 260
NM_000573.3_ex6F gctgtactttgtttctctctcccc 60 50 262
NM_000573.3_ex6R ggcatgtggagaataaagacgc 59 50 262
NM_000573.3_ex7F gcgtctttattctccacatgcc 60 50 182
NM_000573.3_ex7R gcaggtcaggcaagctcata 59 55 182
NM_000573.3_ex8F gggttctcttggctgaaacag 60 52 182
NM_000573.3_ex8R atgaagggagagactggcct 59 55 182
NM_000573.3_ex9F acctctggtgaaactcctga 60 50 330
NM_000573.3_ex9R atggagggcctgggttagat 60 55 330
NM_000573.3_ex10F gaggaaacacactgggtatc 56 50 277
NM_000573.3_ex10R tgcagacatgggaaagatcc 59 50 277
NM_000573.3_ex11F ctctacctggctccaaaaca 57 50 161
NM_000573.3_ex11R accaagagatgttgctgcca 60 50 161
NM_000573.3_ex12F gctgtcaggaagttgatgaggt 60 50 185
NM_000573.3_ex12R taaacggtggggtgaatggg 60 55 185
NM_000573.3_ex13_1F gcaagactctgtcccaaggt 60 55 269
NM_000573.3_ex13_1R tataatgcactgaggggccg 60 55 269
NM_000573.3_ex13_2F cggcccctcagtgcattata 60 55 255
NM_000573.3_ex13_2R acagcaacgcatgtcacttg 60 50 255
NM_000573.3_ex14F gctgtactttgtttctctctcccc 60 50 262
NM_000573.3_ex14R ggcatgtggagaataaagacgc 60 50 262
NM_000573.3_ex15F gcgtctttattctccacatgcc 60 50 214
NM_000573.3_ex15R agactgattcccaaccccaa 59 50 214
NM_000573.3_ex16F gggttctcttggctgaaacag 60 52 182
NM_000573.3_ex16R atgaagggagagactggcct 60 55 182
NM_000573.3_ex17F acctctggtgaaactcctga 60 50 330
NM_000573.3_ex17R atggagggcctgggttagat 60 55 330
NM_000573.3_ex18F gaggaaacacactgggtatc 56 50 277
NM_000573.3_ex18R tgcagacatgggaaagatcc 58 50 277
NM_000573.3_ex19F tcagattactctacctggctcc 60 50 200
NM_000573.3_ex19R gaaagtactatcgctgtgctgg 60 50 200
NM_000573.3_ex20F gctgtcaggaagttgatgaggt 60 50 185
NM_000573.3_ex20R taaacggtggggtgaatggg 60 55 185
NM_000573.3_ex21_1F gcaagactctgtcccaaggt 60 55 296
NM_000573.3_ex21_1R cacatttggaggcgtgcatt 60 60 296
NM_000573.3_ex21_2F cggcccctcagtgcattata 61 55 255
NM_000573.3_ex21_2R acagcaacgcatgtcacttg 60 50 255
NM_000573.3_ex22F gctgtactttgtttctctctcccc 61 50 262
NM_000573.3_ex22R ggcatgtggagaataaagacgc 60 50 262
NM_000573.3_ex23F gcgtctttattctccacatgcc 60 50 182
NM_000573.3_ex23R gcaggtcaggcaagctcata 60 55 182
NM_000573.3_ex24F gtgtcctcttggctgaaacag 60 53 180
NM_000573.3_ex24R tgaaggggagagattggcct 60 55 180
NM_000573.3_ex25F acctctggtgaaactcctga 59 50 330
NM_000573.3_ex25R atggaggggctgggttagat 60 56 330
NM_000573.3_ex26F gaggaaacacactgggtatc 56 50 277
NM_000573.3_ex26R tgcagacatgggaaagatcc 56 55 277
NM_000573.3_ex27F ctctacctggctccaaaaca 60 50 183
NM_000573.3_ex27R atcgctgtgctggaactctt 61 50 183
NM_000573.3_ex28F tgctgtcaggaagttgatgagg 60 50 185
NM_000573.3_ex28R tcaatggtggggtgaatggg 60 55 185
NM_000573.3_ex29_1F gcaagactctgtcccaaggt 59 55 268
NM_000573.3_ex29_1R tataatgcactgaggggcgg 60 55 268
NM_000573.3_ex29_2F ccgcccctcagtgcattata 60 55 264
NM_000573.3_ex29_2R cctgatccaacagcaacaca 60 50 264
NM_000573.3_ex30 ggaagcataggaaattccccca 60 50 294
NM_000573.3_ex30 agtaagacctccatgtgtggg 59 52 294
NM_000573.3_ex31 cacacatggaggtcttactc 60 50 198
NM_000573.3_ex31 gcagtgctgagtccctgatc 59 60 198
NM_000573.3_ex32 atggtgcattcatccagcca 60 50 234
NM_000573.3_ex32 tcaaaagcgggcacaaacag 60 50 234
NM_000573.3_ex33 ggcaacacagtcacagtatg 57 50 370
NM_000573.3_ex33 gggtccacatattctgaaccca 60 50 370
NM_000573.3_ex34 gaggaggtagggtggaagtct 59 72 300
NM_000573.3_ex34 agcccggtcccacctatg 60 66 300
NM_000573.3_ex35 cccaaattctgcttcttcccc 60 52 183
NM_000573.3_ex35 tcagaagttggctctgctgt 60 55 183
NM_000573.3_ex36F ctgccatggtgtaatctgtcct 60 50 255
NM_000573.3_ex36R gggcaagtcaggatcacaca 60 55 255
NM_000573.3_ex37_1F ctcttccttctctcagtc 50 50 316
NM_000573.3_ex37_1R tgatgatctcagtgaggg 52 50 316
NM_000573.3_ex37_2F gagtaccaggaaacaggagt 56 50 181
NM_000573.3_ex37_2R cctcacacccagcaaagtct 59 55 181
NM_000573.3_ex38F caagtgctctggaactgtcct 60 52 262
NM_000573.3_ex38R agtcctccatgtgaagggga 60 55 262
NM_000573.3_ex39F tccccttcacatggaggact 60 55 186
NM_000573.3_ex39R tgagtccttggtctcaacgc 60 55 186
NM_000573.3_ex40F gggagagatgggaattgctca 60 52 222
NM_000573.3_ex40R gacaacaggtgatgccatgc 60 55 222
NM_000573.3_ex41F ttaagcgcacagtcacaggt 59 50 337
NM_000573.3_ex41R ggatatgtggaagcaggtac 56 50 337
NM_000573.3_ex42F gtgtgggaacttgttcttagcc 61 50 253
NM_000573.3_ex42R gcctcatgcattccatacaacc 60 50 253
NM_000573.3_ex43F tgcttcctcttagccaaggg 60 55 326
NM_000573.3_ex43R cccacattccttgcacttgc 61 55 326
NM_000573.3_ex44F tgttgcatgccagagtgatg 59 50 109
NM_000573.3_ex44R gatgccagaattcctcagca 59 50 109
NM_000573.3_ex45F ccttgttttactgcctaggc 59 50 154
NM_000573.3_ex45R tgacttccaagagggggtaag 59 52 154
NM_000573.3_ex46F tcctttcagacgtcttgcaa 57 45 348
NM_000573.3_ex46R ggtatcaatgacctacctagtgca 59 46 348
NM_000573.3_ex47F ctgggtagttcagttgtctacc 58 50 102
NM_000573.3_ex47R cgagatgttcttcagctg 53 50 102
본 발명에서 디자인된 프라이머 (BIN1)
Primer ID 서열 Tm (oC) GC (%) 길이 (bp)
NM_004305.3_ex1_1F ctccctcctcgcggacct 60 72 364
NM_004305.3_ex1_1R acccctttactgcccatctc 60 55 364
NM_004305.3_ex1_2F aagatctccccgcgcgag 60 66 212
NM_004305.3_ex1_2R gaggatagggggacaggtgg 60 65 212
NM_004305.3_ex2F tctccccttctctcttggct 60 55 172
NM_004305.3_ex2R ccatttttcacctggcagcc 60 55 172
NM_004305.3_ex3F tccctgacctggtccttgtc 60 60 138
NM_004305.3_ex3R ctgcacccaccagctctac 60 63 138
NM_004305.3_ex4F ggaggcccacatacttcctt 60 55 188
NM_004305.3_ex4R ggacaggagctgagaccaga 60 60 188
NM_004305.3_ex5F gtgctcttgcctgtctcaga 60 55 170
NM_004305.3_ex5R tctctccagttccctccagg 60 60 170
NM_004305.3_ex6F gcttagtgccctcctctgtc 60 60 183
NM_004305.3_ex6R ctctcagccccctgcaga 61 66 183
NM_004305.3_ex7F ccaacagaggggaatgacc 57 58 132
NM_004305.3_ex7R gctgggcctcacctgttc 60 66 132
NM_004305.3_ex8F ccatccttccgcccttctg 60 63 132
NM_004305.3_ex8R ggtgtggcccctcagagg 61 72 132
NM_004305.3_ex9F cactgtctctcctgcagctc 60 60 176
NM_004305.3_ex9R ccaacagggtcacaggaagg 60 60 176
NM_004305.3_ex10F gaatgaaggcctccacctcc 60 60 141
NM_004305.3_ex10R atgcacagggccagccag 62 67 141
NM_004305.3_ex11F gctccctttcttgtcctccc 60 60 200
NM_004305.3_ex11R gggacctgctaccaagacat 61 55 200
NM_004305.3_ex12F gtcctgtgtctgaccccaag 61 60 162
NM_004305.3_ex12R aggaaaaggcagggctttgt 60 50 162
NM_004305.3_ex13F ctgctcagctgacccgtac 60 63 171
NM_004305.3_ex13R actgcagcagtcagaggct 60 58 171
NM_004305.3_ex14F gggacggaaggtctgacttg 61 60 191
NM_004305.3_ex14R caggatgcctgtggtccc 60 66 191
NM_004305.3_ex15F ctctgcccctcaggatgaag 59 60 371
NM_004305.3_ex15R gggcgccagaaactcaacta 60 55 371
본 발명에서 디자인된 프라이머 (TREM2)
Primer ID 서열 Tm (oC) GC (%) 길이 (bp)
NM_001271821.1_ex1F ccccagtcctgactattgct 60 55 229
NM_001271821.1_ex1R gagggagagaaggcatcaca 60 55 229
NM_001271821.1_ex2F tgaatgtctcctccccagag 60 55 384
NM_001271821.1_ex2R ccactgcccactcacctg 59 66 384
NM_001271821.1_ex3F aggaggaaggggctggag 61 66 185
NM_001271821.1_ex3R ctctgcagggtggaagtctg 61 60 185
NM_001271821.1_ex4F cccatctgccttcttgtctc 61 55 247
NM_001271821.1_ex4R cttgatggctgtgctctcc 60 57 247
본 발명에서 디자인된 프라이머 (CLU)
Primer ID 서열 Tm (oC) GC (%) 길이 (bp)
NM_001831.3_ex1F agcacagctattcgtggtga 59 50 356
NM_001831.3_ex1R gtgactgcgagctgtgtcat 60 55 356
NM_001831.3_ex2F gtgtccatggcaagtctggt 61 55 396
NM_001831.3_ex2R ggcctgatagagaggcactg 60 60 396
NM_001831.3_ex3F tgacagcccctgaactgaac 61 55 399
NM_001831.3_ex3R taattgcagcctcagcatca 61 45 399
NM_001831.3_ex4F ggagcaagggtaggcactt 59 58 396
NM_001831.3_ex4R gcatgcggaatgaagcata 61 47 396
NM_001831.3_ex5_1F gtggccttggtgagcttct 62 55 258
NM_001831.3_ex5_1R gaagggcaggtagtggtagg 64 55 285
NM_001831.3_ex5_2F tccaggacaggttcttcacc 60 55 308
NM_001831.3_ex5_2R cagcatctaacgagttgctca 60 45 308
NM_001831.3_ex6F agagtcacctgagcctggaa 60 55 376
NM_001831.3_ex6R cataaaggcagcaccagtga 60 50 376
NM_001831.3_ex7F catgtgctaacttccattca 55 40 400
NM_001831.3_ex7R tcagtcaaaagcacacatgc 58 45 400
NM_001831.3_ex8F tttccttggagaagcaggag 60 50 392
NM_001831.3_ex8R agtcgttcccaccaggctat 61 55 392
NM_001831.3_ex9F ccaagaacaaagccaggaag 60 50 197
NM_001831.3_ex9R tacttggtgacgtgcagagc 61 55 197
본 발명에서 디자인된 프라이머 (CTNNA3)
Primer ID 서열 Tm (oC) GC (%) 길이 (bp)
XM_005269717.1_ex1F gtgaggtcagtgactagcgg 60 60 309
XM_005269717.1_ex1R gcagaaatgagaattcgctg 56 45 309
XM_005269717.1_ex2F tggagcctttcttgaagcgt 60 50 138
XM_005269717.1_ex2R gccctacaatttagccctgt 59 50 138
XM_005269717.1_ex3F agcatccttttgtgtttgtgca 60 41 134
XM_005269717.1_ex3R aatacctggattatgagaggctcc 61 46 134
XM_005269717.1_ex4F tcccaggactgtgttctcct 60 55 291
XM_005269717.1_ex4R atgcagtttgctcctgacca 61 50 291
XM_005269717.1_ex5F ggggttgtatttttcaggtgaagc 60 46 227
XM_005269717.1_ex5R agtgaagacaatgccaaggt 60 45 227
XM_005269717.1_ex6F tcgactcttcgtgttagcaagt 60 46 228
XM_005269717.1_ex6R tccaccaaggagagctctga 60 55 228
XM_005269717.1_ex7F cccattgtaagataccactc 53 45 329
XM_005269717.1_ex7R cacactttatctttctcccgac 57 46 329
XM_005269717.1_ex8F gccatggagctctaaccataca 60 50 263
XM_005269717.1_ex8R aggcaaaccagtcacctacg 59 55 263
XM_005269717.1_ex9F ttcttctttgcaggctgg 60 50 135
XM_005269717.1_ex9R agcccctatgtttctgactcc 60 52 135
XM_005269717.1_ex10F catttcttctcagctccgca 60 50 216
XM_005269717.1_ex10R ggagcctcattctcctggac 60 60 216
XM_005269717.1_ex11F agtgttgctgcatttccttgc 60 48 165
XM_005269717.1_ex11R agttgtcatacctgtggacaca 60 46 165
XM_005269717.1_ex12F attgcatagtggtgaagtgtgg 59 46 260
XM_005269717.1_ex12R acataccagatacagcaagg 55 45 260
XM_005269717.1_ex13F acacagacacacgcaaaaac 57 45 273
XM_005269717.1_ex13R tgtgcagctgttattggcaac 60 47 273
XM_005269717.1_ex14F caaagaggacaatcttctcc 53 45 249
XM_005269717.1_ex14R ggcattccagatggtgaagaac 60 50 249
XM_005269717.1_ex15F taaggtactgccgcgttgtt 60 50 225
XM_005269717.1_ex15R gcacagccttcagtgacaca 60 55 225
XM_005269717.1_ex16F cacatgttttaggctaagatgactc 58 40 272
XM_005269717.1_ex16R gagaatcttgaggtttcact 53 40 272
XM_005269717.1_ex17F tagccgttctttgggatgcg 60 55 266
XM_005269717.1_ex17R gtccacttgtaagtaactcacctg 60 46 266
XM_005269717.1_ex18F atttagtgcccagatccatc 55 45 210
XM_005269717.1_ex18R acaagggtgtagttactctg 55 45 210
XM_005269717.1_ex19F ttccctacagttggacagtgtc 60 50 355
XM_005269717.1_ex19R aagcagtgtggttaggcagg 60 55 355
본 발명에서 디자인된 프라이머 (DNMBP)
Primer ID 서열 Tm (oC) GC (%) 길이 (bp)
NM_015221.2_ex1F cgctgactcacacgggatc 62 63 130
NM_015221.2_ex1R cggcctctgacctgctttc 62 63 130
NM_015221.2_ex2F caggttataaaacatggaggctgg 60 46 205
NM_015221.2_ex2R atggaaagaagtcagggcctg 60 52 205
NM_015221.2_ex3F tgtccttgtacacagacggg 60 55 256
NM_015221.2_ex3R ttgtcgaaacgggcagactc 60 55 256
NM_015221.2_ex4_1F aggtcaccatctctgctcct 60 55 392
NM_015221.2_ex4_1R tcatccacagtcctcagggg 60 60 392
NM_015221.2_ex4_2F tttgtagagctgttggggcc 60 55 380
NM_015221.2_ex4_2R gaagtttccgggatcctggc 59 60 380
NM_015221.2_ex4_3F gccaggatcccggaaacttc 58 55 398
NM_015221.2_ex4_3R tctaggggaagaaggtcggg 57 60 398
NM_015221.2_ex4_4F cacccgcactcagaacagta 60 55 387
NM_015221.2_ex4_4R ccctgccaagctcttctcaa 60 55 387
NM_015221.2_ex4_5F ttgagaagagcttggcaggg 60 55 396
NM_015221.2_ex4_5R atggggaggtctggtccag 60 63 396
NM_015221.2_ex4_6F ggccctggtcatatgggaag 60 60 300
NM_015221.2_ex4_6R ctgggtaggctgtttctggg 60 60 300
NM_015221.2_ex5F tacacccagagctgctaacc 60 55 300
NM_015221.2_ex5R atcctaatgcttctggcctgg 60 52 300
NM_015221.2_ex6F ccattaagctcatttccgtgca 60 46 181
NM_015221.2_ex6R agctgcttctgaaacaacacag 60 46 181
NM_015221.2_ex7F gtgtgtattccaaaggacctgtg 59 47 180
NM_015221.2_ex7R gtggtcaaaactcctacttcag 58 47 180
NM_015221.2_ex8F tcttttcatgcccactgcct 60 50 75
NM_015221.2_ex8R gagcgcatacatcaagcagc 60 55 75
NM_015221.2_ex9F ccttctcttacaggggatgca 60 52 250
NM_015221.2_ex9R gggcatacctccttttcagca 60 52 250
NM_015221.2_ex10F gcccatgctgaggaaagtgc 60 60 200
NM_015221.2_ex10R cgctaagccttccaggatgg 60 60 200
NM_015221.2_ex11F tgtccagatttgctaacagc 60 45 199
NM_015221.2_ex11R aggggacagaattacatcgt 60 45 199
NM_015221.2_ex12F gtgtctgtcctaactggctcc 60 55 183
NM_015221.2_ex12R ggggccaacttttgaagaaa 57 55 183
NM_015221.2_ex13F gcaatgtgcctttctcgtcc 59 55 391
NM_015221.2_ex13R tgaccatcccactgaacagg 61 55 391
NM_015221.2_ex14F ctctgctcttcccatggacc 60 60 219
NM_015221.2_ex14R cagttccctactcaccaggc 60 60 219
NM_015221.2_ex15F acgtcttacctttcagccaagt 60 46 248
NM_015221.2_ex15R cagttacagtcctctgctgct 55 52 248
NM_015221.2_ex16_1F tcctttgtagtcaccaaaggct 60 46 397
NM_015221.2_ex16_1R tggcagtgggttgctttaca 60 50 397
NM_015221.2_ex16_2F ggggactctgcagatgtagc 60 60 274
NM_015221.2_ex16_2R cgctggtacccacaacacat 60 55 274
NM_015221.2_ex17F tctctccctcacacaggtct 60 55 369
NM_015221.2_ex17R acaacccaatcgaggagaaca 60 48 369
본 발명에서 디자인된 프라이머 (SORL1)
Primer ID 서열 Tm (oC) GC (%) 길이 (bp)
NM_003105.5_ex1F cccgttcctattcaccctgg 59 60 395
NM_003105.5_ex1R aggaagtgcagggagaggaa 60 55 395
NM_003105.5_ex2F cgtgggtcctaattcctaca 46 50 194
NM_003105.5_ex2R gttgatggcaccaaggtgtg 61 55 194
NM_003105.5_ex3F ctctgtattccaggtgtacgtg 60 50 173
NM_003105.5_ex3R gaagtcgggacaggagggat 60 60 173
NM_003105.5_ex4F gggcctgctctcaacttacc 60 60 201
NM_003105.5_ex4R ttacctgcttgttggggtgg 60 55 201
NM_003105.5_ex5F agcgggtgtttgatggtgat 60 50 235
NM_003105.5_ex5R tttcaggggagggcagtttg 61 55 235
NM_003105.5_ex6F tgcaaaacttccatgcctct 60 45 315
NM_003105.5_ex6R cacagaatgccaaacttcac 60 45 315
NM_003105.5_ex7F tttctcctcttccttggcagc 60 52 180
NM_003105.5_ex7R ctgacctctgcataaagaca 55 45 180
NM_003105.5_ex8F cccacagggcacatttgttt 60 50 254
NM_003105.5_ex8R aggcaggagaaggactcaca 60 55 254
NM_003105.5_ex9F gtgaatgtgcttaatgccac 57 45 374
NM_003105.5_ex9R aaactaccacagagcagggc 60 55 374
NM_003105.5_ex10F tgctgacactgcctgaaact 60 50 181
NM_003105.5_ex10R accccttttgagaacaggca 60 50 181
NM_003105.5_ex11F cttgcattttaggctcagtggg 60 50 120
NM_003105.5_ex11R ggtggaggggacgggatt 60 67 120
NM_003105.5_ex12F cacagcagtggtgtcacc 60 61 150
NM_003105.5_ex12R aaaggcctcatcagagacac 60 50 150
NM_003105.5_ex13F gcatttgggcagatacagtacc 60 50 218
NM_003105.5_ex13R aaaaggtccaaggaggcagc 60 55 218
NM_003105.5_ex14F tgcctctaatgcttcgtgct 60 50 263
NM_003105.5_ex14R aacacaactcagtccccagc 60 55 263
NM_003105.5_ex15F aaccgtggccttaacaaagc 55 50 185
NM_003105.5_ex15R gcaacctctgtgatacataccc 60 50 185
NM_003105.5_ex16F ctgacctcttgctcttgggg 60 60 191
NM_003105.5_ex16R cggacttgggtgagatcgtg 59 60 191
NM_003105.5_ex17F aacctcccacgtgtcttgtg 60 55 238
NM_003105.5_ex17R cacagctcccacagtcagac 61 60 238
NM_003105.5_ex18F cagggggtcgtttgaacagt 60 55 229
NM_003105.5_ex18R cccgcctgctcccttaatta 60 55 229
NM_003105.5_ex19F ctcagcctcttttccccctg 60 60 165
NM_003105.5_ex19R agcattggacgcaagactga 60 60 165
NM_003105.5_ex20F ccccattttcgctagggtga 61 55 314
NM_003105.5_ex20R tatgctcctcacccgctcta 63 55 314
NM_003105.5_ex21F gctggactaatgggcaaagg 61 55 228
NM_003105.5_ex21R cgcagcccctttcttgagat 60 55 228
NM_003105.5_ex22F tgctgctgtttgtcttccct 60 50 234
NM_003105.5_ex22R aggaggatgacaggcaaa 60 50 234
NM_003105.5_ex23F ggtttcatttcctcccctgc 60 50 180
NM_003105.5_ex23R gtgcttaacgtccaatccag 60 55 180
NM_003105.5_ex24F ccagtaggatgtttacatttgtggg 61 44 232
NM_003105.5_ex24R ctccagagcagggtttcagg 60 60 232
NM_003105.5_ex25F gcttttgtcctcacctctctgt 60 50 200
NM_003105.5_ex25R aacggatgagtgctgtcaact 60 48 200
NM_003105.5_ex26F gtgtgcgactgtgtctctct 60 55 229
NM_003105.5_ex26R tctgtggcctctcttcctga 60 55 229
NM_003105.5_ex27F cctcctcgtcattcttctgtgt 61 50 190
NM_003105.5_ex27R cactaggcctgagtgcttcc 60 60 190
NM_003105.5_ex28F cagtgctcatggcctcttcc 60 60 190
NM_003105.5_ex28R ctgcctgccccaactcac 60 66 190
NM_003105.5_ex29F ggaagttcctggacttcatgga 60 50 195
NM_003105.5_ex29R aggaggcagactggacatct 60 55 195
NM_003105.5_ex30F atgcagggaaagcaactg 60 50 192
NM_003105.5_ex30R ccccaggggcctcttacc 61 72 192
NM_003105.5_ex31F ttttgggtttccgtgcttgg 61 50 222
NM_003105.5_ex31R ggtaccacaggagaggacct 60 60 222
NM_003105.5_ex32F gttattggccagctccctca 60 55 224
NM_003105.5_ex32R gctctctgactactcacggc 60 60 224
NM_003105.5_ex33F ccctccccgtggacttaaga 60 60 185
NM_003105.5_ex33R tggaccggcactcaccac 61 66 185
NM_003105.5_ex34F cgcccagccaagatgtaact 60 55 240
NM_003105.5_ex34R acagaacatcctggggcaat 60 50 240
NM_003105.5_ex35F acggagtcagacatctcagc 60 55 250
NM_003105.5_ex35R gaaacacttacatccctctggg 60 50 250
NM_003105.5_ex36F ctctggttggctgctatgca 60 55 214
NM_003105.5_ex36R ctagcacccccaacacacat 60 55 214
NM_003105.5_ex37F atgccctggacctttggttc 60 55 183
NM_003105.5_ex37R ggctggaatggatgacgaca 60 55 183
NM_003105.5_ex38F ctcacccctttagctcattcag 60 50 186
NM_003105.5_ex38R ctgcaaatgctgggatca 61 50 186
NM_003105.5_ex39F agtcctgccttcctcacttt 60 50 187
NM_003105.5_ex39R ataaagccccatccagctgc 60 55 187
NM_003105.5_ex40F cttcttggttctcggcaggt 60 55 173
NM_003105.5_ex40R agcattggtccagccttacc 60 55 173
NM_003105.5_ex41F cacagttggcaatctgacagc 60 52 244
NM_003105.5_ex41R agcattaggggacagtccac 60 55 244
NM_003105.5_ex42F catgagctgatgtcctcttcca 60 50 176
NM_003105.5_ex42R cggtatgggaaacttacc 52 50 176
NM_003105.5_ex43F ttcctacgtgtgtgcttggg 61 55 212
NM_003105.5_ex43R ctggaagcccaacccactc 60 63 212
NM_003105.5_ex44F ggtcctagttgtatgcagttgc 60 50 217
NM_003105.5_ex44R gtgtgagaagacctctaacctctc 60 50 217
NM_003105.5_ex45F tccactaaccgcatcccatc 62 55 227
NM_003105.5_ex45R ccagcatgctgtcaacaagc 61 55 227
NM_003105.5_ex46F cgacttcctgagcaatctcttg 61 50 257
NM_003105.5_ex46R gacagaaacgggcagcaatc 58 55 257
NM_003105.5_ex47F ggtgggcttattggtgggaa 60 55 276
NM_003105.5_ex47R gaagaaccgactctccctgc 60 60 276
NM_003105.5_ex48F ttggaactcaccaaggcctg 60 55 382
NM_003105.5_ex48R gacgtaaaagcatgcccagc 60 55 382
본 발명에서 디자인된 프라이머 (BACE1)
Primer ID 서열 Tm (oC) GC (%) 길이 (bp)
NM_012104.4_ex1_1F cacaagtctttccgcctccc 61 60 372
NM_012104.4_ex1_1R tctcaggagagggagcttgg 60 60 372
NM_012104.4_ex1_2F ccaagctccctctcctgaga 60 60 397
NM_012104.4_ex1_2R gctaagggctggcctgac 59 60 397
NM_012104.4_ex2F ctctcccctttctctgacagc 60 57 180
NM_012104.4_ex2R ccctcccctgacccttctta 60 60 180
NM_012104.4_ex3F gccttctttccacaggtcca 60 55 240
NM_012104.4_ex3R cctctcaccctggcaatctc 60 60 240
NM_012104.4_ex4F ccaacctcttctccctgcag 60 60 129
NM_012104.4_ex4R tctctccctcaatgccagga 60 55 129
NM_012104.4_ex5F gtgccaggacacgggtac 60 66 192
NM_012104.4_ex5R tctcccttggttttcttacctcc 60 48 192
NM_012104.4_ex6F taaccccctactgcccagag 60 60 185
NM_012104.4_ex6R tagtccactcacggaggagg 60 60 185
NM_012104.4_ex7F ccccttcttgccaacacaga 60 55 202
NM_012104.4_ex7R agagagatccccctgactcag 60 57 202
NM_012104.4_ex8F catttgccctctccccagtg 60 60 400
NM_012104.4_ex8R tcaaggcagaggcatttggt 60 60 400
본 발명에서 디자인된 프라이머 (PICALM)
Primer ID 서열 Tm (oC) GC (%) 길이 (bp)
NM_001206947.1_ex1F taatcaccacagcagtcagc 60 50 298
NM_001206947.1_ex1R aggcctctctctaccatgga 60 55 298
NM_001206947.1_ex2F tcttttgcctgtttgtatgcag 60 41 321
NM_001206947.1_ex2R cctgggagctgtttctgaag 60 55 321
NM_001206947.1_ex3F tcgaattagagttggtgagatggc 59 46 200
NM_001206947.1_ex3R actctggagtaatcatcatgtggg 61 46 200
NM_001206947.1_ex4F gccattggatgcaatgagttgt 58 46 322
NM_001206947.1_ex4R tgaggctcatcttttaaaactggc 61 42 322
NM_001206947.1_ex5F tttcataacagggctgatggag 58 46 192
NM_001206947.1_ex5R gagtctgtgaaaacttgagg 53 45 192
NM_001206947.1_ex6F ttcactaacatgcctaatgc 54 40 245
NM_001206947.1_ex6R aggctacagcagtatttaccca 59 46 245
NM_001206947.1_ex7F tgctcctttagagacctatttgg 59 43 356
NM_001206947.1_ex7R ttgccacagaattcaatacagc 60 41 356
NM_001206947.1_ex8F ctggtactagccgtgatgtca 59 52 169
NM_001206947.1_ex8R cacaacagatagtggattgg 53 45 169
NM_001206947.1_ex9F tacaattgcaggcccctagc 59 55 162
NM_001206947.1_ex9R agctggtttcatctactgcct 59 47 162
NM_001206947.1_ex10F gccagaccatttcatgacctg 61 52 274
NM_001206947.1_ex10R ctgtgcagaggccccattta 60 55 274
NM_001206947.1_ex11F tctggaatccttatggtagttccc 60 46 191
NM_001206947.1_ex11R ccttaacttctactcctacctg 55 46 191
NM_001206947.1_ex12F atctgtggtgggtggagaag 60 55 336
NM_001206947.1_ex12R ccttcaagggataaaattgc 56 40 336
NM_001206947.1_ex13F gtgtggggaatttagtgc 54 50 345
NM_001206947.1_ex13R gggggatgggacaatttct 61 53 345
NM_001206947.1_ex14F ggagaaaaggcaaagacctc 58 50 339
NM_001206947.1_ex14R agtggttccatttccgatgc 62 50 339
NM_001206947.1_ex15F agtggcctctcagaaccaga 60 55 384
NM_001206947.1_ex15R aacagagcgagactccgtgt 60 55 384
NM_001206947.1_ex16F ctcccaaagtgctgggatta 60 50 397
NM_001206947.1_ex16R taggcaaccagcttcctttg 60 50 397
NM_001206947.1_ex17F ctcacagctgtcttagca 50 50 284
NM_001206947.1_ex17R gggctaggagtatgaggagca 61 57 284
NM_001206947.1_ex18F ggacctgtcatccctgttgt 60 55 222
NM_001206947.1_ex18R accacagttacatgtagtgtgt 57 41 222
NM_001206947.1_ex19F ggtaaagaccacaaagcatt 54 40 370
NM_001206947.1_ex19R acaggagttgaaagaattgaaggg 59 42 370
본 발명에서 디자인된 프라이머 (LRP6)
Primer ID 서열 Tm (oC) GC (%) 길이 (bp)
NM_002336.2_ex1F ctcgcctcccccacttct 60 66 152
NM_002336.2_ex1R accccaccaactttccagtg 61 55 152
NM_002336.2_ex2_1F tttttgttctagcggcccct 59 50 250
NM_002336.2_ex2_1R tcgggggacaataatccaga 60 50 250
NM_002336.2_ex2_2F ctgagagtgtgcagaatg 53 50 262
NM_002336.2_ex2_2R gtcagtggagaaaaaccg 53 50 262
NM_002336.2_ex2F tctagcggcccctttgttg 60 57 400
NM_002336.2_ex2R cccacttgaaggatctaaggca 60 50 400
NM_002336.2_ex3F tgatatctgctctgtcatggct 59 46 300
NM_002336.2_ex3R tgtatcaaggcttcatcgag 55 45 300
NM_002336.2_ex4F tgttaataggcaggcagtggt 60 48 322
NM_002336.2_ex4R attcccgccaactatctttg 56 45 322
NM_002336.2_ex5F tgacagccacaaatccatgt 58 45 250
NM_002336.2_ex5R aagtgactggtctcccaaagc 60 52 250
NM_002336.2_ex6_1F cactttgttgttctaggtgcca 59 45 256
NM_002336.2_ex6_1R caggatgggcaatttgagcag 59 52 256
NM_002336.2_ex6_2F tggatctggcagtcagtttgt 59 48 220
NM_002336.2_ex6_2R cagtagagcttcttacccaacca 59 48 220
NM_002336.2_ex7F ctaggtacatgtattggactgactgg 60 46 235
NM_002336.2_ex7R actgtcgactcaaaacccat 57 45 235
NM_002336.2_ex8F gcataattcatccccttctc 54 46 296
NM_002336.2_ex8R cctggttcccatttctaagaaagc 60 46 296
NM_002336.2_ex9F gtgtccttctgtgccccttt 60 55 375
NM_002336.2_ex9R gttctcccttttagtccctagct 59 48 375
NM_002336.2_ex10F ctggatagggtttagacttatgcc 60 46 342
NM_002336.2_ex10R tgccatgttccccgaaatgt 59 50 342
NM_002336.2_ex11F gactctttcccccagataat 54 45 305
NM_002336.2_ex11R cagccactgatatttgcatgga 59 46 305
NM_002336.2_ex12F actctgcttctcccctgtct 60 55 390
NM_002336.2_ex12R gctttggagggaaatgcagc 60 55 390
NM_002336.2_ex13F tggatgatagaggatgtagggt 58 46 318
NM_002336.2_ex13R tggtgagtccagttattagtcagg 59 46 318
NM_002336.2_ex14F ttgcctcagggttatctgcc 60 55 307
NM_002336.2_ex14R agccacagtatctgaacgcc 59 55 307
NM_002336.2_ex15F ttcctcctttccctctaggt 59 50 312
NM_002336.2_ex15R actgccaagaaatgtgccaa 61 45 312
NM_002336.2_ex16F aacttgacccacatgagtca 56 45 290
NM_002336.2_ex16R cctccaattagctttatccc 53 45 290
NM_002336.2_ex17F acttctctccccctccactc 59 60 222
NM_002336.2_ex17R tgcatttagggttgcacaag 60 45 222
NM_002336.2_ex18F tgtcactccccttctccttg 59 55 307
NM_002336.2_ex18R aaaggattgcatgctgaggc 59 50 307
NM_002336.2_ex19F gccagagtttgactttacatga 60 41 190
NM_002336.2_ex19R agatctcagtcctacttacaacaatcc 60 41 190
NM_002336.2_ex20F actgcattcttcattgtagatccg 59 41 300
NM_002336.2_ex20R agtcttgcaggaccaaagact 59 47 300
NM_002336.2_ex21F attttaggaatgtctcgagg 52 40 180
NM_002336.2_ex21R atgtatgtcgcattcaaagg 54 40 180
NM_002336.2_ex22F tgaggaagccatagtcccaa 59 50 302
NM_002336.2_ex22R gcaccttattttagagaaggatgtg 61 40 302
NM_002336.2_ex23F ctgcttctctttattttctccc 55 41 355
NM_002336.2_ex23R gttggaggcagtcagaggag 60 60 355
본 발명에서 디자인된 프라이머 (PSEN1)
Primer ID 서열 Tm (oC) GC (%) 길이 (bp)
NM_007318.2_ex1F gaaatgacgacaacggtgag 60 50 166
NM_007318.2_ex1R actccccatcacgcacatac 60 50 166
NM_007318.2_ex2F tggatgacctggtgaaatcc 61 60 214
NM_007318.2_ex2R agcctcttgaggttctga 53 50 214
NM_007318.2_ex3F ttggcctggaggagaacac 61 58 300
NM_007318.2_ex3R tccagtctggcaaaggcagt 63 55 300
NM_007318.2_ex4F ccgttaccttgattctgctg 60 50 354
NM_007318.2_ex4R gccacactggctttgagaat 60 55 354
NM_007318.2_ex5F cactgacctagggcttttgtg 60 52 220
NM_007318.2_ex5R gaagaacagggtggaaagca 60 50 220
NM_007318.2_ex6F tttaagggttgtgggacctg 60 50 176
NM_007318.2_ex6R gctacacagcacaaaggtagtt 56 45 176
NM_007318.2_ex7F tgtttgggagccatcaca 60 50 348
NM_007318.2_ex7R gggcattcctgtgacaaaca 59 50 348
NM_007318.2_ex8F attcctccctaccacccatt 59 50 239
NM_007318.2_ex8R catgtgcttcagttccgata 57 45 239
NM_007318.2_ex9F ggagaaatgatggcttgttg 58 45 219
NM_007318.2_ex9R gcttataacagtgaccctga 53 45 219
M_007318.2_ex10F gagctgtaacttccactttctc 55 46 250
M_007318.2_ex10R gctacctaaaggaatccatgac 56 46 250
M_007318.2_ex11F cattgtggggttgagtaggg 60 55 309
M_007318.2_ex11R ccacctggggttaaaacaga 60 50 309
M_007318.2_ex12F gtgtgtctttcccatcttctcc 60 50 241
M_007318.2_ex12R acctttgtcctccccagatt 60 50 241
본 발명에서 디자인된 프라이머 (ADAM10)
Primer ID 서열 Tm (oC) GC (%) 길이 (bp)
NM_001110.2_ex1F agccccttcagcttctccc 61 63 152
NM_001110.2_ex1R gcagtcgtgcctcacctc 60 60 152
NM_001110.2_ex2F gaaggggtcttcaagatgat 55 45 238
NM_001110.2_ex2R ggaacttcagacacagtcagc 58 53 238
NM_001110.2_ex3F gttgttcccccttcccatcc 60 60 173
NM_001110.2_ex3R gggttctgttaaggtccaac 56 50 173
NM_001110.2_ex4F aggtgaagaaggaagttttagcca 60 42 280
NM_001110.2_ex4R tgttctagcctgattagtaactcag 58 40 280
NM_001110.2_ex5F tgccttttccataggtgctt 57 45 275
NM_001110.2_ex5R ccatttcctaaatgcaagctagtgt 60 40 275
NM_001110.2_ex6F tggcagcagaaatacctatggt 59 46 313
NM_001110.2_ex6R tgggaactactaaaatagcgca 57 41 313
NM_001110.2_ex7F aatctcccttcccagcgcag 62 60 328
NM_001110.2_ex7R acatagtctggactgtttcact 58 41 328
NM_001110.2_ex8F cattcacactaaagctctgc 55 45 296
NM_001110.2_ex8R ctcccctttgtttcaagtag 54 45 296
NM_001110.2_ex9F acctttttgggggtaagggg 60 55 236
NM_001110.2_ex9R gacaatacttactggggatcca 60 46 236
NM_001110.2_ex10F ggagagtccacaagcttcca 60 55 395
NM_001110.2_ex10R atgcaggtggtgggtatgtc 60 55 395
NM_001110.2_ex11F attttcctcagaatctggcc 56 45 182
NM_001110.2_ex11R cactgaaattagcaaggtacctgc 60 46 182
NM_001110.2_ex12F ttcctctagtccaagtcaaggtc 58 47 200
NM_001110.2_ex12R tgcttaccccattaatgcacac 58 45 200
NM_001110.2_ex13F ggaagctcatacttgcctgtc 59 52 293
NM_001110.2_ex13R tctggccaaactgtaggtca 59 50 293
NM_001110.2_ex14F gcatttcttttccagtggaccc 60 50 310
NM_001110.2_ex14R ttgatgacttctggccaagt 57 47 310
NM_001110.2_ex15F tttctaggctcattggtggg 55 50 252
NM_001110.2_ex15R cccattcttacggagaaagtactg 60 46 252
NM_001110.2_ex16F ggcccatattattggacagcac 60 50 246
NM_001110.2_ex16R gcactaggaagaaccaaggca 60 52 246
본 발명에서 디자인된 프라이머 (ABCA7)
Primer ID 서열 Tm (oC) GC (%) 길이 (bp)
NM_019112.3_ex1F ttctgtgatcccgtctcctc 60 55 354
NM_019112.3_ex1R attcagccgtcgtcaacatt 61 45 354
NM_019112.3_ex2F gcgctcccattggtttact 60 53 400
NM_019112.3_ex2R aagagaggccacagcaattc 59 50 400
NM_019112.3_ex3F gtaacgccccagtgtgagac 61 60 376
NM_019112.3_ex3R cctgtggactctgcctgact 60 60 376
NM_019112.3_ex4F ccaatacatggcatgggagt 61 50 359
NM_019112.3_ex4R gaccctggggacagagaga 60 63 359
NM_019112.3_ex5F gcctgagcaacttcaacgac 61 55 397
NM_019112.3_ex5R gtggagactgcttggttggt 60 55 397
NM_019112.3_ex6F agctctgagcctcaacttgc 60 55 380
NM_019112.3_ex6R cagacgagtcttcctcactgg 60 57 380
NM_019112.3_ex7F gacccagtgaggaagactcg 60 60 395
NM_019112.3_ex7R cctctccctctcgctgtcta 60 60 395
NM_019112.3_ex8F gatcattgccagctccgtct 60 55 261
NM_019112.3_ex8R ggtcagtcactcactcaggc 60 60 261
NM_019112.3_ex9F cagacagcagcctgagtgag 60 60 370
NM_019112.3_ex9R cctccatcggctaactccta 59 55 370
NM_019112.3_ex10F cttgtgcggaggatcagag 60 58 360
NM_019112.3_ex10R cagagcgagactccatctca 59 55 360
NM_019112.3_ex11F ctcctgacctcaggtgatcc 60 60 393
NM_019112.3_ex11R aaatcccaggctcttactaggg 60 50 393
NM_019112.3_ex12F gaggtccagggggaggag 62 72 398
NM_019112.3_ex12R tctccaataggctgaatgctg 60 48 398
NM_019112.3_ex13F gattgcagctcttcactcca 59 50 392
NM_019112.3_ex13R caggaaggttcccaacagag 60 55 392
NM_019112.3_ex14F gtctccagcctccacccc 61 72 295
NM_019112.3_ex14R acccattctgcagccggg 62 66 295
NM_019112.3_ex15F gctggagggtgacagacag 59 63 397
NM_019112.3_ex15R agcaggctctgcggaaaa 62 56 397
NM_019112.3_ex16F actgaccgcccgcttttc 60 61 278
NM_019112.3_ex16R cctcccgcaaagcaggtg 61 67 278
NM_019112.3_ex17F agcttgcagcgagtcaaaat 60 45 390
NM_019112.3_ex17R agtgtcttcagggcaggtgt 60 55 390
NM_019112.3_ex18F catgacctccatggctgagt 60 55 227
NM_019112.3_ex18R gagtggttgggggctcac 60 67 227
NM_019112.3_ex19F gggcaacagagtgaaactcc 60 55 391
NM_019112.3_ex19R gtgcacagagcagagtgacc 60 60 391
NM_019112.3_ex20F gctgtttgacatgtgcgtct 60 50 351
NM_019112.3_ex20R ctacccacgtggacctcagt 60 60 351
NM_019112.3_ex21F gaagccgggtactgaggtc 60 63 331
NM_019112.3_ex21R ggggtccacatgtagcaaac 60 55 331
NM_019112.3_ex22F cttcatggggcagacaactc 61 55 388
NM_019112.3_ex22R actgccctccatgtcagtgt 61 55 388
NM_019112.3_ex23F tgaccaccaatgagaaggtg 60 50 349
NM_019112.3_ex23R ccccttccacctcttactcc 60 60 349
NM_019112.3_ex24F acagtcccctcacaggtcac 60 60 395
NM_019112.3_ex24R ccttgctgctcataaacacg 59 50 395
NM_019112.3_ex25F agctctggtggctcagatgt 60 55 319
NM_019112.3_ex25R aagttgagggtcacggattg 60 50 319
NM_019112.3_ex26F ccaaggcatagcctttaccc 61 55 387
NM_019112.3_ex26R agaaagcgcttgagaagcag 60 50 387
NM_019112.3_ex27F gacgtaaccctacggctcaa 60 55 376
NM_019112.3_ex27R ggtttggattaggccactga 60 50 376
NM_019112.3_ex28F agccatgggtggttgtagag 60 55 304
NM_019112.3_ex28R tcactgtgtgtgaggggaga 60 55 304
NM_019112.3_ex29F gtacggtgctcaggtgtcct 60 60 392
NM_019112.3_ex29R agggtcaaggtgaaggtctg 59 55 392
NM_019112.3_ex30F ttgagtgtgcacagcccatt 60 50 330
NM_019112.3_ex30R ggacccatgctatagccagg 60 60 330
NM_019112.3_ex31F ttgactctgtgctcccctct 60 55 259
NM_019112.3_ex31R agcgagaagcctccgtatct 61 55 259
NM_019112.3_ex32F ggtgaggaggggtctagctt 60 60 388
NM_019112.3_ex32R ggtgggggtcaaggtcatag 62 60 388
NM_019112.3_ex33F agtctcaaggtgggaactgg 59 55 365
NM_019112.3_ex33R tgtgtcagggttcaaatcca 60 45 365
NM_019112.3_ex34F tgactgccccatagaccttt 60 50 383
NM_019112.3_ex34R actttacccaggccatcttg 59 50 383
NM_019112.3_ex35F caaaaagcaaggaggtcagg 60 50 362
NM_019112.3_ex35R cttggcacaccactgaattg 60 50 362
NM_019112.3_ex36F gcagagaagatgggaatgga 60 50 380
NM_019112.3_ex36R aagcagaagtgggggaagat 60 50 380
NM_019112.3_ex37F atgtggtgctcacctgcata 60 50 387
NM_019112.3_ex37R ggggctgtttttctccactc 61 55 387
NM_019112.3_ex38F gactccagctgagtggccta 61 60 354
NM_019112.3_ex38R aggagtggcagagacctcac 59 60 354
NM_019112.3_ex39F acctcttggccatggtgata 60 50 360
NM_019112.3_ex39R tacctgggagagtgcaggtc 60 60 360
NM_019112.3_ex40F tgttggtgctgaggaacttg 60 50 287
NM_019112.3_ex40R gtgcccaataaaaggtggtg 60 50 287
NM_019112.3_ex41F aaggcaggagaattgcttga 60 45 380
NM_019112.3_ex41R ccagtccattcactggaggt 60 55 380
NM_019112.3_ex42F agacccctgcacctctacct 60 60 384
NM_019112.3_ex42R gattgggccaggctttaga 60 53 384
NM_019112.3_ex43F ctgctccacactcaatgctg 61 55 370
NM_019112.3_ex43R caaaaggctgttccaaagga 60 45 370
NM_019112.3_ex44F ctacagcggagggaacaaac 60 55 339
NM_019112.3_ex44R cctgtggccttgtgcttt 60 56 339
NM_019112.3_ex45F agaacggtctggggaagagt 60 55 367
NM_019112.3_ex45R cccctgcaggacaatctaaa 60 50 367
NM_019112.3_ex46F gaaaggcccgatccggtag 60 63 290
NM_019112.3_ex46R cgtgatcacctcctccagc 60 63 290
NM_019112.3_ex47F tccctcttgtcccctctgg 60 63 365
NM_019112.3_ex47R cctggctcaaggacacacat 60 55 365
본 발명에서 디자인된 프라이머 (CD33)
Primer ID 서열 Tm (oC) GC (%) 길이 (bp)
NM_001772.3_ex1F ttctgctcacacaggaagcc 60 55 138
NM_001772.3_ex1R gtggggaaacgagggtcag 60 63 138
NM_001772.3_ex2_1F gaccctcgtttccccacag 60 63 246
NM_001772.3_ex2_1R gccctgagtctcctcctgta 60 60 246
NM_001772.3_ex2_2F ggccacaaacaagctagatc 56 50 245
NM_001772.3_ex2_2R acccatgaacttcccttgcg 60 55 245
NM_001772.3_ex3F ggaccctccctcctgattct 60 55 376
NM_001772.3_ex3R atcctgtctcccctacaccc 60 55 376
NM_001772.3_ex4F acccccaactgaaggaaatcc 60 52 124
NM_001772.3_ex4R atgtcagtaacagccccagg 61 55 124
NM_001772.3_ex5F acccctctctacatgctgga 59 55 223
NM_001772.3_ex5R ctcttcacctctggcccatg 60 60 223
NM_001772.3_ex6F cccacagcctgagaaaacca 60 55 190
NM_001772.3_ex6R ccacattgggaggaggtgtc 60 60 190
NM_001772.3_ex7F ctcactgccctgctctaacc 60 60 271
NM_001772.3_ex7R gtccccgacctgtagaggat 60 60 271
본 발명에서 디자인된 프라이머 (APP)
Primer ID 서열 Tm (oC) GC (%) 길이 (bp)
NM_001136131.2_ex1F gggctccgtcagtttcct 60 61 311
NM_001136131.2_ex1R cccggcttctctgcatta 60 55 311
NM_001136131.2_ex2F ctctgccttggagctatgga 61 55 240
NM_001136131.2_ex2R tagccaccggacaggactta 61 55 240
NM_001136131.2_ex3F cacttctggtcccaagcatt 60 50 375
NM_001136131.2_ex3R gagtggcaatgtgctgaaga 60 50 375
NM_001136131.2_ex4F tagggtcttgattgggttgc 60 50 339
NM_001136131.2_ex4R gctgttgcctcaaaataccc 60 50 339
NM_001136131.2_ex5F cactttgtagacatgcagtgag 56 46 221
NM_001136131.2_ex5R cacaaaggccaccttacctc 60 56 221
NM_001136131.2_ex6F ggacgacttttcttttccttcc 58 46 363
NM_001136131.2_ex6R cagtggtgctagggtggata 58 55 363
NM_001136131.2_ex7F aatgtggttccccacatctc 59 50 257
NM_001136131.2_ex7R agcagagtcagtggcgagag 60 60 257
NM_001136131.2_ex8F gtggactcgtgcatttcagc 61 55 192
NM_001136131.2_ex8R gtgaaccaagcagcatcctc 60 55 192
NM_001136131.2_ex9F tctcaaacctccttctcttc 53 45 205
NM_001136131.2_ex9R cccaatatcgtagggctgaa 59 50 205
NM_001136131.2_ex10F tcctagtgggaggtcaaa 54 50 331
NM_001136131.2_ex10R ggtaggaaatgggttcaggt 58 50 331
NM_001136131.2_ex11F tcagtccccatggacata 55 50 306
NM_001136131.2_ex11R gtgctcaaggcatttctcct 59 50 306
NM_001136131.2_ex12F tacgttcacatgaccggatg 60 50 355
NM_001136131.2_ex12R cttgccatagggaaaacacc 59 50 355
NM_001136131.2_ex13F aaccattcctacccccagac 60 55 205
NM_001136131.2_ex13R ctgggggaaaatacatgtcc 60 50 205
NM_001136131.2_ex14F tgctgctgctgctgttgt 60 55 359
NM_001136131.2_ex14R ctctctctcttgcacacacg 59 55 359
NM_001136131.2_ex15F ttctgtgtcccttgcttcct 60 50 105
NM_001136131.2_ex15R cacaagtcaagcggttctga 60 50 105
NM_001136131.2_ex16F gggtaggctttgtcttacagtg 58 50 228
NM_001136131.2_ex16R ggcaagacaaacagtagtgg 56 55 228
NM_001136131.2_ex17F caaccagttgggcagagaat 60 50 334
NM_001136131.2_ex17R ccacttggaaacatgcagtc 60 50 334
NM_001136131.2_ex18F agctctcctcttgtttttcagg 59 45 220
NM_001136131.2_ex18R gggtttgtttcttcccacat 58 45 220
본 발명에서 디자인된 프라이머 (PINK1)
Primer ID 서열 Tm (oC) GC (%) 길이 (bp)
NM_032409.2_ex1_1F gctgctgctgcgcttcac 62 67 350
NM_032409.2_ex1_1R ccccgctcacctggatct 60 67 350
NM_032409.2_ex1_2F cagcggcagttcgtggtg 61 66 187
NM_032409.2_ex1_2R ttagctccgtcctccgct 60 61 187
NM_032409.2_ex2F tcccttttcttgggccttcc 61 55 367
NM_032409.2_ex2R tgaaaggcctggtgcttacc 60 55 367
NM_032409.2_ex3F cctgtgtaaccctgggttcc 60 60 164
NM_032409.2_ex3R gtcagtctggcaggcagag 61 63 164
NM_032409.2_ex4F tgtatctgatgctggcctca 58 50 270
NM_032409.2_ex4R gatgtatcagctccaggccc 60 60 270
NM_032409.2_ex5F agtcgtcgatgtgtggtagc 60 55 230
NM_032409.2_ex5R atggtgcagcaggttcctac 60 55 230
NM_032409.2_ex6F tggtcactttgcttgctcct 50 55 209
NM_032409.2_ex6R cagtggacatgtgggggaag 60 50 209
NM_032409.2_ex7F gtgatgtctcacccactgct 60 55 309
NM_032409.2_ex7R gtttctacccacaccgtccc 59 60 309
NM_032409.2_ex8F gcttcccttcctgttgcaga 60 55 384
NM_032409.2_ex8R tctctgcgctgtcttgtctc 60 55 384
본 발명에서 디자인된 프라이머 (PARK7)
Primer ID 서열 Tm (oC) GC (%) 길이 (bp)
NM_007262.4_ex1F gggctgtccagctagaaact 59 55 316
NM_007262.4_ex1R gtccagcacagggacacc 60 67 316
NM_007262.4_ex2F ctctgcttgaaaatgctcct 57 45 375
NM_007262.4_ex2R gcgttaaatgtgagcagtgg 59 50 375
NM_007262.4_ex3F gagctggaggctgcagtaag 60 60 376
NM_007262.4_ex3R ggggaagacattcaagcaaa 60 45 376
NM_007262.4_ex4F acaccattccgtcatgtgg 60 53 348
NM_007262.4_ex4R cctcctcccgaaatatttgaa 60 43 348
NM_007262.4_ex5F atgagaaatgccttgcttgg 60 45 386
NM_007262.4_ex5R agatgccctgcatgctttat 60 45 386
NM_007262.4_ex6F tctacctaggcctccccaat 60 55 311
NM_007262.4_ex6R tgcagtaagccaagatcacg 60 50 311
NM_007262.4_ex7F tgcaggtcattacacctactctg 60 48 381
NM_007262.4_ex7R gccctgtttattctgcaaac 57 45 381
본 발명에서 디자인된 프라이머 (PARK9 ( atp13a2 ))
Primer ID 서열 Tm (oC) GC (%) 길이 (bp)
XM_005245809.1_ex1F ggtgtgtgcggaggagca 62 64 333
XM_005245809.1_ex1R gacccggactccgcactc 62 65 333
XM_005245809.1_ex2F ctcccaaagtgctgggatta 60 50 372
XM_005245809.1_ex2R tccatggactgccacagtag 60 55 372
XM_005245809.1_ex3F aaagctgcagggggtgaat 62 53 388
XM_005245809.1_ex3R gtcccatggaaagtcagtgg 60 55 388
XM_005245809.1_ex4F ctcagctttcccatctgagc 60 55 325
XM_005245809.1_ex4R gccagagtcagcctttatgg 60 55 325
XM_005245809.1_ex5F tagggagggaagatggctct 60 55 332
XM_005245809.1_ex5R tggatgtttgggacaacaga 60 45 332
XM_005245809.1_ex6F tctgttgtcccaaacatcca 60 45 398
XM_005245809.1_ex6R gtaacctgcccaaggtttca 60 50 398
XM_005245809.1_ex7F ggaacccagtgagaggaaca 60 55 359
XM_005245809.1_ex7R agagaaggcaggtgactgga 60 55 359
XM_005245809.1_ex8F tccagtcacctgccttctct 60 55 316
XM_005245809.1_ex8R ccactatggagaaggggaca 60 55 316
XM_005245809.1_ex9F gatgggattgaccaggagaa 60 50 380
XM_005245809.1_ex9R agagtctggctttgctgtgg 61 55 380
XM_005245809.1_ex10F cctcatttcctccatctcca 60 50 330
XM_005245809.1_ex10R cactggagtccacccactct 60 60 330
XM_005245809.1_ex11F gggaggtgaggagctaggg 61 68 381
XM_005245809.1_ex11R cagcctggacaacagagtga 60 55 381
XM_005245809.1_EX12F aactcctggtttgctggtgg 60 55 253
XM_005245809.1_EX12R gatctctctcaagcccagcc 59 50 253
XM_005245809.1_ex13F ctccacactgctgatggcta 60 55 377
XM_005245809.1_ex13R cggtttcggtagaggatgaa 60 50 377
XM_005245809.1_ex14F cctctctgtcctgggtgagt 59 60 266
XM_005245809.1_ex14R gagcccggattacaatctca 60 50 266
XM_005245809.1_ex15F cctctaccgaaaccgggta 60 58 390
XM_005245809.1_ex15R gtgggtgctgctgagagaat 60 55 390
XM_005245809.1_ex16F agttcctggggttcccatag 60 55 398
XM_005245809.1_ex16R aagatggagagggaagacagg 60 52 398
XM_005245809.1_ex17F gctgggagatttggagtgac 60 55 390
XM_005245809.1_ex17R ctcctgcagggttggagag 61 63 390
XM_005245809.1_ex18F cagtgatgagacccccactt 60 55 390
XM_005245809.1_ex18R gaggcaggtgtcacaaggag 61 60 390
XM_005245809.1_ex19F ctctgcaaccccgagacag 62 63 388
XM_005245809.1_ex19R acctggatcagaggtcatgc 60 55 388
XM_005245809.1_ex20F cccacccactctgaggacta 60 60 353
XM_005245809.1_ex20R aagatgccccaaaaaggaat 60 40 353
XM_005245809.1_ex21F cagcctgttttcccatctgt 60 50 396
XM_005245809.1_ex21R gtgtagcttgcagcctggtc 61 60 396
XM_005245809.1_ex22F ccagctgtacctcacccagt 60 60 395
XM_005245809.1_ex22R ccagctctgtcttctgctca 59 55 395
XM_005245809.1_ex23F cccctgctctgtctccttc 60 63 321
XM_005245809.1_ex23R catgaaagacctgggagagc 60 55 321
XM_005245809.1_ex24F ggcccagctgtcatcatatt 60 50 363
XM_005245809.1_ex24R gacgctgaacgaagtgtcaa 60 50 363
XM_005245809.1_ex25F gcagaagcctcagtggtctc 60 60 358
XM_005245809.1_ex25R gcccacgtcatctattctgg 60 55 358
XM_005245809.1_ex26F tatcagactaggggctgcca 59 55 307
XM_005245809.1_ex26R agtcagctccctactcacca 59 55 307
XM_005245809.1_ex27F agctagggggctacttcctg 60 60 364
XM_005245809.1_ex27R ggcacctctctcccatctg 61 63 364
XM_005245809.1_ex28F gactacaagtcccggcagc 60 63 362
XM_005245809.1_ex28R ctccaaggggtgacgacaac 60 60 362
본 발명에서 디자인된 프라이머 (SNCA)
Primer ID 서열 Tm (oC) GC (%) 길이 (bp)
NM_001146055.1_ex1F cctcacgccttgccttcaa 59 58 100
NM_001146055.1_ex1R ggagtgggaggcaaaccc 60 67 100
NM_001146055.1_ex2F tccccgaaagttctcattca 57 45 235
NM_001146055.1_ex2R ccatcactcatgaacaagcacc 60 50 235
NM_001146055.1_ex3F aggctagcttgagacttatg 52 45 150
NM_001146055.1_ex3R atactgggccacactaatcac 57 48 150
NM_001146055.1_ex4F agtcactgttattctaccaccc 57 46 210
NM_001146055.1_ex4R tacacagccataccttgccc 60 55 210
NM_001146055.1_ex5F ttcaagatccgtggccaaca 60 50 221
NM_001146055.1_ex5R tcagcttggactcctacctca 60 52 221
NM_001146055.1_ex6F cagtgtgtgctgtctttttg 56 45 101
NM_001146055.1_ex6R agatctcaagaaactgggagca 59 45 101
본 발명에서 디자인된 프라이머 (LRRK2)
Primer ID 서열 Tm (oC) GC (%) 길이 (bp)
NM_198578.3_ex1F ttcctcataaacaggcgggc 60 55 311
NM_198578.3_ex1R ggagtacgtgaacaccagca 60 55 311
NM_198578.3_ex2F tccccacccacttgttttcc 60 55 172
NM_198578.3_ex2R gccagtaaaacgtctccttcc 58 52 172
NM_198578.3_ex3F cttgttttcaggtgggttggtc 60 50 201
NM_198578.3_ex3R acacagtgtatcaagggaaggt 55 45 201
NM_198578.3_ex4F acacatgagcttcactacaggg 60 50 340
NM_198578.3_ex4R gctaccctaatcctgatcttca 56 46 340
NM_198578.3_ex5F aaccatgggtctacaaacca 55 45 325
NM_198578.3_ex5R ctgtgttctacttttcccag 54 45 325
NM_198578.3_ex6F ttaagtctcagaggagcaactgac 60 49 255
NM_198578.3_ex6R gggttgagcatccacaagtt 58 50 255
NM_198578.3_ex7F gaaatgcagtcattatgctgcc 59 46 251
NM_198578.3_ex7R tcacctaatgtaagcctatggagc 60 46 251
NM_198578.3_ex8F cttccatggatgagaattcagc 58 46 180
NM_198578.3_ex8R tagtgaagttacttactgaggagggc 61 46 180
NM_198578.3_ex9F agcacacctcattctgttggt 60 48 264
NM_198578.3_ex9R gagagtcctacctgcacgtg 59 60 264
NM_198578.3_ex10F cgtggcatagaaagaacaagca 60 46 205
NM_198578.3_ex10R actaactggccatcttcatctcc 60 47 205
NM_198578.3_ex11F ctcttgtaagtggaggtggca 60 52 259
NM_198578.3_ex11R tggcccactgcttaccattt 60 50 259
NM_198578.3_ex12F gctttcctgtaaatttggac 53 40 283
NM_198578.3_ex12R ttctacctggcccaatatga 56 45 283
NM_198578.3_ex13F atattggttctgccctcctg 57 50 234
NM_198578.3_ex13R ctatgtaacttaccaggcac 53 45 234
NM_198578.3_ex14F gcatttaggcatgccagaaga 60 48 200
NM_198578.3_ex14R actgaaaaagcgcccctagt 60 50 200
NM_198578.3_ex15F agttcattggaaatcctggg 60 45 210
NM_198578.3_ex15R tccagtcaccagctaatgcc 60 55 210
NM_198578.3_ex16F ggcattagctggtgactgga 60 55 271
NM_198578.3_ex16R gtgaaattcgcacaagttccca 60 46 271
NM_198578.3_ex17F actttaaagcaccaaccca 56 42 280
NM_198578.3_ex17R acactgtacctgttgatcct 56 45 280
NM_198578.3_ex18F aggatcaacaggtacagtgt 60 45 325
NM_198578.3_ex18R acaatggcagggctcttaca 59 50 325
NM_198578.3_ex19_1F ttgccagtctcctaaaagga 56 45 209
NM_198578.3_ex19_1R gccagcctccttaagagcaa 60 55 209
NM_198578.3_ex19_2F gcgttgacgataagcattggg 60 52 280
NM_198578.3_ex19_2R ggtccctcaaactggcatga 60 55 280
NM_198578.3_ex20F tctccagaagcatagcaatacg 60 45 375
NM_198578.3_ex20R ttaggtcaggtttttgtcttgg 58 41 375
NM_198578.3_ex21F caaagggaatggactgtgaaa 60 43 364
NM_198578.3_ex21R catcagggaaatccctacca 60 50 364
NM_198578.3_ex22F tcatttgagcactgaactggag 60 45 362
NM_198578.3_ex22R agatgaaactggcaccaagaa 60 43 362
NM_198578.3_ex23F gggtcatcaaaacttcaatccc 58 46 395
NM_198578.3_ex23R tgctcctgaacatcacacaga 60 48 395
NM_198578.3_ex24F agttaccagaggtgtgtaaggc 59 50 390
NM_198578.3_ex24R catcagcatatttaggcaaccc 61 46 390
NM_198578.3_ex25F cctctttgatgctgttctttga 59 41 337
NM_198578.3_ex25R aaatccacaactaaagggtcca 60 41 337
NM_198578.3_ex26F gtgacacactattggtagctgt 52 46 237
NM_198578.3_ex26R ggttctgttccagctaatgtgc 52 50 237
NM_198578.3_ex27F acactttattctcaccctgggg 59 50 304
NM_198578.3_ex27R gtggcaataatcgtcttacctc 59 46 304
NM_198578.3_ex28F cttccttcccaccaacaggt 59 55 300
NM_198578.3_ex28R tgtccatcaaagtcacagagag 59 46 300
NM_198578.3_ex29F actaggtttcttcaacagcg 58 45 290
NM_198578.3_ex29R ccctgttccaaacaaatggt 57 45 290
NM_198578.3_ex30F ggctgtgccttataaccgaa 60 50 240
NM_198578.3_ex30R acacgcacacagacacatga 60 50 240
NM_198578.3_ex31F gtgaatgtcacggaaagcaa 59 45 325
NM_198578.3_ex31R cagcctaccatgttaccttgaa 59 45 325
NM_198578.3_ex32F actgttagcactgaatttgc 53 40 397
NM_198578.3_ex32R gaaccgtatggatattctctca 56 41 397
NM_198578.3_ex33F gaccataggatgcacagcttc 59 52 306
NM_198578.3_ex33R gcgccatctgttctatgctt 60 60 306
NM_198578.3_ex34F ggtactgtgttgcacttgaa 55 45 333
NM_198578.3_ex34R ggttttctttacctgcttgg 57 45 333
NM_198578.3_ex35F gctcaacaaggttgggtgtt 61 50 298
NM_198578.3_ex35R tgccatctccctaatttctc 60 45 298
NM_198578.3_ex36F caatcacttgtgttgtgtgcag 60 46 327
NM_198578.3_ex36R aacctcatactgtcgcaaagc 59 48 327
NM_198578.3_ex37F aagctttgcgacagtatgagg 59 48 261
NM_198578.3_ex37R caaaacataccttcctctgc 59 45 261
NM_198578.3_ex38F tggttagaaagggagggatt 58 45 275
NM_198578.3_ex38R ttacctaggagaaactctgg 52 45 275
NM_198578.3_ex39F attcaatgaaacaagtaggtcagg 60 40 380
NM_198578.3_ex39R ccacaacgaaaagacaaactagg 60 43 380
NM_198578.3_ex40F catgttcagcctgttgatgc 60 50 385
NM_198578.3_ex40R tgttactggggcacagtgtt 59 50 385
NM_198578.3_ex41F tgcattttctggcagatacc 60 45 233
NM_198578.3_ex41R gaggtcagtggttatccatcct 59 50 233
NM_198578.3_ex42F gagccctgatgttggtcata 58 50 239
NM_198578.3_ex42R tgtagagaaaacagaacttaccag 55 38 239
NM_198578.3_ex43F ctttgcaatgtctggacctttt 59 41 200
NM_198578.3_ex43R aatacctgggcagaagtaggc 60 52 200
NM_198578.3_ex44F tggtgatctagttgggttcca 60 48 349
NM_198578.3_ex44R gagcatttggatttacctcaga 60 41 349
NM_198578.3_ex45F caggaagttgctgatagtagaa 54 49 236
NM_198578.3_ex45R gatctgtaatttccccattg 54 40 236
NM_198578.3_ex46F gggaagagtctgggaaaagg 60 55 351
NM_198578.3_ex46R atcccataagaggggtgtga 59 50 351
NM_198578.3_ex47F ggcaaagcttaaaggagctg 59 50 372
NM_198578.3_ex47R acccttctgctttctggaat 57 45 372
NM_198578.3_ex48F ctctgtaggttttcttatgcagctt 60 40 256
NM_198578.3_ex48R ttcagaggcagaaaggaagaa 60 43 256
NM_198578.3_ex49F tttatggttctagggaggtaatgg 60 42 241
NM_198578.3_ex49R ctaaaggaaagaaacttgcctagc 60 42 241
NM_198578.3_ex50_1F tctagagatacaatcttgcttgacc 59 40 255
NM_198578.3_ex50_1R aacattccttcatacacacgag 60 41 255
NM_198578.3_ex50_2F agctcgtgtgtatgaaggaatg 56 46 282
NM_198578.3_ex50_2R tcgacaagcaatagtcctgtctt 60 44 282
NM_198578.3_ex51_1F tctagagatacaatcttgcttgacc 59 40 255
NM_198578.3_ex51_1R aacattccttcatacacacgag 58 40 255
NM_198578.3_ex51_2F tagctcgtgtgtatgaaggaatg 59 43 370
NM_198578.3_ex51_2R gtgcatttcgatgcaatct 57 42 370
본 발명에서 디자인된 프라이머 (TDP-43)
Primer ID 서열 Tm (oC) GC (%) 길이 (bp)
XM_005263435.1_ex1F ccgaaaccatctgctacgtt 60 50 329
XM_005263435.1_ex1R gaagcccgacagggacac 61 67 329
XM_005263435.1_ex2F tcagaactctgacatggtttgg 60 46 389
XM_005263435.1_ex2R cacctgaacacacttcagca 59 50 389
XM_005263435.1_ex3F tttgggaatggagtgtgtga 61 45 223
XM_005263435.1_ex3R ccaaagcacagacgcaagta 61 55 223
XM_005263435.1_ex4F cagcaaagccaagatgagc 59 52 251
XM_005263435.1_ex4R ctcggcctccaaagtgct 60 61 251
XM_005263435.1_ex5_1F gattgcgcagtctctttgtg 59 50 383
XM_005263435.1_ex5_1R cctggtttggctccctct 60 61 383
XM_005263435.1_ex5_2F ggccttcggttctggaaata 61 52 397
XM_005263435.1_ex5_2R caggcaaacagcagttca 57 55 397
XM_005263435.1_ex5_3F ggtaaaccaacacactacaa 51 40 389
XM_005263435.1_ex5_3R cttgaatgagaaagcatgtagacag 59 40 389
XM_005263435.1_ex5_4F atcacaggccgcgtcttt 61 57 350
XM_005263435.1_ex5_4R tccaacagatgtggatgtcct 60 48 350
XM_005263435.1_ex5_5F cccctacccctttgtcaact 60 55 392
XM_005263435.1_ex5_5R gttccatctcaaaagggtca 57 45 392
XM_005263435.1_ex5_6F tgacccttttgagatggaac 57 45 371
XM_005263435.1_ex5_6R atcaacattttgcccactcc 59 45 371
XM_005263435.1_ex5_7F aagggaatatcagcaccttcc 59 47 203
XM_005263435.1_ex5_7R gttaccacattcccccacct 60 55 203
본 발명에서 디자인된 프라이머 (SIGMAR1)
Primer ID 서열 Tm (oC) GC (%) 길이 (bp)
XM_005251339.1_ex1F ccgattggtcagggcgag 59 68 264
XM_005251339.1_ex1R atctcttcgcgctggaagac 59 55 264
XM_005251339.1_ex2F ggtgccagccctgactcc 62 72 286
XM_005251339.1_ex2R ctttacaaccccagcctccc 60 60 286
XM_005251339.1_ex3F tgtgcgattgtcactcaggg 59 55 152
XM_005251339.1_ex3R cgtgaagggacccacttctc 60 60 152
XM_005251339.1_ex4_1F aggggagacggtagtacacg 60 60 400
XM_005251339.1_ex4_1R ccatgggtctctgtgtttgga 61 53 400
XM_005251339.1_ex4_2F tgcagatcctgagttcctgc 60 55 399
XM_005251339.1_ex4_2R aagggcatcatagctgcagg 60 55 399
XM_005251339.1_ex4_3F cctgcagctatgatgccctt 60 55 373
XM_005251339.1_ex4_3R aggggctgtgtgaaaactgt 60 50 373
본 발명에서 디자인된 프라이머 (FUS)
Primer ID 서열 Tm (oC) GC (%) 길이 (bp)
NM_004960.3_ex1F acttaagcttcgacgcagga 60 50 200
NM_004960.3_ex1R cccggtcccactgaaaac 61 61 200
NM_004960.3_ex2F ggcctacgtggtccttttta 60 50 200
NM_004960.3_ex2R cagaaaacatggcgtgacc 60 52 200
NM_004960.3_ex3F ctgatcacgctggttttcct 60 50 200
NM_004960.3_ex3R cccgctgagaaagactcact 60 55 200
NM_004960.3_ex4F ctctttcctggtggcttttg 61 55 233
NM_004960.3_ex4R acccctcttttcaagccttc 60 55 233
NM_004960.3_ex5F ggctatgctgggattgtgat 60 50 261
NM_004960.3_ex5R gctgcagacaaagctgaaga 60 50 261
NM_004960.3_ex6F cctggcacttgtcaaacctt 60 50 344
NM_004960.3_ex6R atgagacacctaccccatgc 60 55 344
NM_004960.3_ex7F ctacccatgtttggggaatg 60 50 179
NM_004960.3_ex7R gacaaagcattgctgggagt 60 45 179
NM_004960.3_ex8F cggctcatcttttccttg 56 50 151
NM_004960.3_ex8R tccaggcagtcttgataccac 60 52 151
NM_004960.3_ex9F ctgttcaacaagcagaacagga 60 46 170
NM_004960.3_ex9R tccacaagcctacaacactga 59 47 170
NM_004960.3_ex10F tggaaagggagtactgtagcc 60 52 210
NM_004960.3_ex10R tctgccagccttctcataca 60 50 210
NM_004960.3_ex11F agaaaggcacgcttctcttg 60 50 218
NM_004960.3_ex11R cattacccctctgcaccact 60 55 218
NM_004960.3_ex12F caaacttggagagggagcag 60 55 214
NM_004960.3_ex12R gcacgcatgcaagagaacta 60 50 214
NM_004960.3_ex13F aggtcttgcctattccccatc 60 52 200
NM_004960.3_ex13R ggattctttggtcccagctc 60 55 200
NM_004960.3_ex14F ctcggggaacataggggaat 62 55 252
NM_004960.3_ex14R atggcctctgttcaactgct 60 50 252
NM_004960.3_ex15F cttggagaggctggtaactca 60 52 159
NM_004960.3_ex15R cgagggtaacactgggtacag 62 57 `159
본 발명에서 디자인된 프라이머 (GRN)
Primer ID 서열 Tm (oC) GC (%) 길이 (bp)
NM_002087.2_ex1F ggccaatggaaactgaggta 60 50 133
NM_002087.2_ex1R gagcaggcgagaggtctg 60 67 133
NM_002087.2_ex2F ggcttaagcagttgccagac 60 55 242
NM_002087.2_ex2R gatgaccctttgggaaaacc 60 50 242
NM_002087.2_ex3F ccaggcacaagtctgtggtt 61 55 208
NM_002087.2_ex3R cagacctaagcccctccact 60 60 208
NM_002087.2_ex4F gccaatgcaggtttctctgt 60 50 172
NM_002087.2_ex4R ggttccagactccacatgct 60 55 172
NM_002087.2_ex5F ggagtcaccttccctgagtg 60 60 200
NM_002087.2_ex5R cctccacatacccccatct 60 57 200
NM_002087.2_ex6F ggggtgaagacggagtcag 60 63 201
NM_002087.2_ex6R ccctggcctgatgctctc 60 67 201
NM_002087.2_ex7F ctcacgtttgctcctcttcc 60 55 150
NM_002087.2_ex7R ctccagcccctcactcac 60 67 150
NM_002087.2_ex8F gcctggaagtgacaaagacc 60 55 225
NM_002087.2_ex8R caggcctaaaagggaggaaa 60 50 225
NM_002087.2_ex9F cctctctgcttccctcacag 60 60 160
NM_002087.2_ex9R gcctgccacactgtgctc 61 67 160
NM_002087.2_ex10F cacctgcccttcttcatctg 60 55 292
NM_002087.2_ex10R tgctgtcccctcccatatac 60 55 292
NM_002087.2_ex11F ggctacctacaacgcccttt 60 55 315
NM_002087.2_ex11R ctgggcttagctcccctatc 60 60 315
NM_002087.2_ex12F cagtgaggggacaggaacat 60 55 318
NM_002087.2_ex12R catacccagccccaggat 60 61 318
NM_002087.2_ex13F cacctcgtccaaccctctc 61 63 279
NM_002087.2_ex13R ggtccagggagaatttggtt 60 50 279
본 발명에서 디자인된 프라이머 (MAPT)
Primer ID 서열 Tm (oC) GC (%) 길이 (bp)
NM_001203251.1_ex1F actagtggccggaggagaag 61 60 306
NM_001203251.1_ex1R gacggcgaggcagatttc 61 61 306
NM_001203251.1_ex2F ccccaacactcctcagaact 60 55 212
NM_001203251.1_ex2R gcatggctgtccactaacct 60 55 212
NM_001203251.1_ex3F cgttctgagggctcactgta 60 55 177
NM_001203251.1_ex3R ctcaaagcacggctaagcac 61 55 177
NM_001203251.1_ex4F ggtgaggggctgggtatg 61 66 180
NM_001203251.1_ex4R gactgcctgggggtctct 60 66 180
NM_001203251.1_ex5F ccccttcatttgctgacac 60 52 126
NM_001203251.1_ex5R caagtcatggcaggcaattc 55 50 126
NM_001203251.1_ex6F_1 acagagcctgaaagtggtaagg 60 50 400
NM_001203251.1_ex6R_1 ggatgctggtggcttctct 60 57 400
NM_001203251.1_ex6F_2 cagagaagccaccagcatc 60 57 400
NM_001203251.1_ex6R_2 gcgaagaagctcaagacaca 59 50 400
NM_001203251.1_ex7F caaacatggacctatcccagag 60 50 200
NM_001203251.1_ex7R aacttgaccagctgcagagc 60 55 200
NM_001203251.1_ex8F cagtttgtttccctcctcca 60 50 300
NM_001203251.1_ex8R gcagagcagcctggttctt 60 57 300
NM_001203251.1_ex9F ggtggcagtaacttttcc 53 50 231
NM_001203251.1_ex9R tctgagagcttcagcttcctct 60 50 231
NM_001203251.1_ex10F ctcgagtcctggcttcactc 60 60 363
NM_001203251.1_ex10R acagccctacccctccag 60 67 363
NM_001203251.1_ex11F cgcatgtcactcatcgaaag 60 50 253
NM_001203251.1_ex11R cgcactcacaccacttccta 60 55 253
NM_001203251.1_ex12F ttcctctctctctgcctttcc 60 52 161
NM_001203251.1_ex12R gtcccaaccctcaccttcc 60 53 161
NM_001203251.1_ex13F ccacagaagatgatggcaag 60 50 202
NM_001203251.1_ex13R catatacccaagggcagcat 60 50 202
NM_001203251.1_ex14F ctcaccctccctcccttc 60 66 300
NM_001203251.1_ex14R ccacactctctcattctctcctc 60 55 300
본 발명에서 디자인된 프라이머 (ALS2)
Primer ID 서열 Tm (oC) GC (%) 길이 (bp)
NM_020919.3_ex1F ggtagctaggcttggacgac 60 60 390
NM_020919.3_ex1R ttagccaatagccaacccgg 61 55 390
NM_020919.3_ex2F gcacttgttagagggctgct 59 55 217
NM_020919.3_ex2R tgctatgttttcctaggagg 60 45 217
NM_020919.3_ex3F gatgttttagctcaacagaggcag 60 46 220
NM_020919.3_ex3R ctcaggcatttgttagcattgc 60 46 220
NM_020919.3_ex4_1F accttcagatggtgaggtct 60 50 397
NM_020919.3_ex4_1R tgggaaggcagtggtaatgag 59 52 397
NM_020919.3_ex4_2F cattaccactgccttcccagt 60 52 400
NM_020919.3_ex4_2R gctgcttgtgatctgagcac 60 55 400
NM_020919.3_ex4_3F gtgctcagatcacaagcagc 60 55 281
NM_020919.3_ex4_3R gctaccaagccttactca 54 50 281
NM_020919.3_ex5_1F gcgatggatattagcctttc 54 45 284
NM_020919.3_ex5_1R ctgcctgagctccagtttca 60 55 284
NM_020919.3_ex5_2F atgaagctggtgccttgtca 60 50 305
NM_020919.3_ex5_2R atgcgatgtcaggagcatcc 60 55 305
NM_020919.3_ex6F cttcaccccacgtctggttg 60 60 221
NM_020919.3_ex6R tcggtaaatgttggtagcgct 60 48 221
NM_020919.3_ex7F tgactttgtgtgcctgtgtg 59 50 180
NM_020919.3_ex7R tgttggccttccatgaaaat 60 40 180
NM_020919.3_ex8F cgcttagctacttttctgtg 55 46 220
NM_020919.3_ex8R taggttgtacgtatgaaattcccccg 62 46 220
NM_020919.3_ex9F ctgtcgttgcagataagcagtg 60 50 228
NM_020919.3_ex9R gaatgtgggccttaggatcca 60 52 228
NM_020919.3_ex10F gccagcttcagtatacca 54 50 276
NM_020919.3_ex10R taatggtgggagagaggggg 60 50 276
NM_020919.3_ex11F ccttagttgagagcacatggc 60 53 333
NM_020919.3_ex11R tgaacatgacacgggactgg 60 55 333
NM_020919.3_ex12F ccaggtatgtgtttggaaactg 60 46 182
NM_020919.3_ex12R tggcggagagaatgataactgg 60 50 182
NM_020919.3_ex13F tcctctgcctctagtgatttcc 60 50 203
NM_020919.3_ex13R ccaaagaggtatacatgggagc 60 50 203
NM_020919.3_ex14F aggcagactgaggctacaga 60 55 257
NM_020919.3_ex14R tggttgctgtttgctagggt 60 50 257
NM_020919.3_ex15F tccaggattccttgagga 60 50 154
NM_020919.3_ex15R aggttaggaatccagcctacct 59 50 154
NM_020919.3_ex16F aagtgcctccgtgttctctg 60 55 135
NM_020919.3_ex16R cttggacggggtggggtg 60 72 135
NM_020919.3_ex17F gcccaaaaccaagcaagcat 60 50 245
NM_020919.3_ex17R ccagggcgaagattgaagga 59 55 245
NM_020919.3_ex18F tgctcctagacaaagtggct 60 50 250
NM_020919.3_ex18R tcatcctcaccccaggcata 60 55 250
NM_020919.3_ex19F tggggtgaggatgatcatca 60 50 207
NM_020919.3_ex19R acgaccttaccgaacttg 60 50 207
NM_020919.3_ex20F tcatggcaggtatggaga 54 50 140
NM_020919.3_ex20R aaacaccagtccaacagcct 60 50 140
NM_020919.3_ex21F ccattctttccaaccacagc 57 50 212
NM_020919.3_ex21R ctgtgggaatagaaggag 51 50 212
NM_020919.3_ex22F ttatttctgtgcaggggg 54 50 274
NM_020919.3_ex22R cgcagtcatatccccaaagc 60 55 274
NM_020919.3_ex23F cttcttgtagggaaatgggg 55 50 203
NM_020919.3_ex23R aacgtgcacttgaaaggggt 60 50 203
NM_020919.3_ex24F ctctgactttacctaggg 50 50 324
NM_020919.3_ex24R gcactccagcctggtgac 60 57 324
NM_020919.3_ex25F gcaggaagctaggaaacctgg 60 57 252
NM_020919.3_ex25R tgtggtgagccttgactact 57 50 252
NM_020919.3_ex26F ggatgctccactttgactgga 60 52 307
NM_020919.3_ex26R gctgtgagtctatctgaatg 53 45 307
NM_020919.3_ex27F tcctactcaggcctgtgaca 60 55 206
NM_020919.3_ex27R ttccatagcccgcagacttt 60 50 206
NM_020919.3_ex28F ccccctagaggtataattgt 53 45 171
NM_020919.3_ex28R ccctggctctggtgattcag 60 60 171
NM_020919.3_ex29F gctccttttctcccactcca 60 55 241
NM_020919.3_ex29R ccatttggttgcgcttgt 59 50 241
NM_020919.3_ex30F tctctggggcaggattagga 59 55 300
NM_020919.3_ex30R tgaggaacaactggcttatcct 60 46 300
NM_020919.3_ex31F tcctccttgaccttcactctct 59 50 197
NM_020919.3_ex31R tggggatgcttaaggcttagg 60 52 197
NM_020919.3_ex32F agtgtccgggttaaggcatg 60 55 275
NM_020919.3_ex32R aaaacagttacctggcccgt 60 50 275
NM_020919.3_ex33F tctctggggcaggattagga 60 55 300
NM_020919.3_ex33R tgaggaacaactggcttatcct 59 46 300
NM_020919.3_ex34_1F gaacttttcttccaggcatg 60 45 373
NM_020919.3_ex34_1R gctgacataccctttactgtagga 59 46 373
NM_020919.3_ex34_2F atcccttcctacagtaaagggt 60 46 370
NM_020919.3_ex34_2R gaggcagaagactcctatttgga 60 48 370
NM_020919.3_ex34_3F aggagtcttctgcctcttaact 58 46 390
NM_020919.3_ex34_3R ccaacaacttacaatagggc 54 45 390
본 발명에서 디자인된 프라이머 (CSF1R)
Primer ID 서열 Tm (oC) GC (%) 길이 (bp)
NM_005211.3_ex1F cagctgctagagcccagatt 60 55 192
NM_005211.3_ex1R ctattccctcccctgtcctt 60 55 192
NM_005211.3_ex2F aaactctgtggttgccttgc 60 50 313
NM_005211.3_ex2R tcacaggggtcttctccatc 60 55 313
NM_005211.3_ex3F gcgcatcctagacctcactt 61 55 331
NM_005211.3_ex3R cttgggaggaggctcagac 60 63 331
NM_005211.3_ex4F agggcagttgtaaccctgtg 59 55 371
NM_005211.3_ex4R ctctgtccccactcttcagg 60 60 371
NM_005211.3_ex5F ctgggtgttcaggggtctct 61 60 190
NM_005211.3_ex5R tgtgatctgcagggactgac 60 55 190
NM_005211.3_ex6F ctcgcaatccctcaacaatc 60 50 200
NM_005211.3_ex6R aggatccctaccgactgtcc 60 60 200
NM_005211.3_ex7F cccactaatgccagatgctt 60 50 283
NM_005211.3_ex7R gcataccccatctggttgtc 60 55 283
NM_005211.3_ex8F catactaggctggggctcac 60 60 222
NM_005211.3_ex8R ccatccctccaggcagtc 60 66 222
NM_005211.3_ex9F ctgggagattgggaggtg 60 61 199
NM_005211.3_ex9R tgagtggagcccacttacct 60 55 199
NM_005211.3_ex10F ctgaagctctgagccacattc 60 52 240
NM_005211.3_ex10R gaaggctccctctcacctg 60 63 240
NM_005211.3_ex11F ctcactgctttgcttcatgc 60 50 199
NM_005211.3_ex11R accatccaaatctggctcac 60 50 199
NM_005211.3_ex12F acgtgctcccttcctcttct 60 55 194
NM_005211.3_ex12R gccctgtgataggaagctgt 61 55 194
NM_005211.3_ex13F gggacttaagggacctgtgtg 60 57 189
NM_005211.3_ex13R cacccccagcatctaccac 60 63 189
NM_005211.3_ex14F cctgtctttgggactgtggt 60 55 200
NM_005211.3_ex14R ccctgagattccccagagg 61 63 200
NM_005211.3_ex15F cacacccttggctgctcta 60 57 221
NM_005211.3_ex15R cagacctggcctttttcttg 60 50 221
NM_005211.3_ex16F tgagcagtgcagtgatgatg 60 50 203
NM_005211.3_ex16R cccttctccttttcccttgt 60 50 203
NM_005211.3_ex17F gtgaggggtggggagtgt 60 66 170
NM_005211.3_ex17R agggccaggttcctactcac 60 60 170
NM_005211.3_ex18F ggtaggagaaggcccaagac 60 60 183
NM_005211.3_ex18R ccctcccagcacttacattg 60 55 183
NM_005211.3_ex19F gcccaaaataactggggact 60 50 201
NM_005211.3_ex19R agtggggcaaccagaggag 62 63 201
NM_005211.3_ex20F gggaatggggagaagacaat 60 50 172
NM_005211.3_ex20R gggatcccttcgcttacata 60 50 172
NM_005211.3_ex21F tgggcatcctctgtcctatc 60 55 185
NM_005211.3_ex21R cagcccaacgtgctttacc 61 58 185
NM_005211.3_ex22F gcctgatggatctggactga 59 55 244
NM_005211.3_ex22R agtttgtgggaggggagagt 60 55 244
본 발명에서 디자인된 프라이머 (NOTCH3)
Primer ID 서열 Tm (oC) GC (%) 길이 (bp)
NM_000435.2_ex1F cagggaaggagggaggag 59 66 222
NM_000435.2_ex1R cttgggggttcttgcactc 60 57 222
NM_000435.2_ex2F tccttcacccccacacag 60 61 116
NM_000435.2_ex2R ctctgagccaggcactcac 60 63 116
NM_000435.2_ex3F cccaaccaagccatctctg 60 57 203
NM_000435.2_ex3R cgactacctcccctccagac 60 65 203
NM_000435.2_ex4F tcctaaactcaccctgtcctg 60 52 381
NM_000435.2_ex4R ggctcactcaccaggaagac 59 60 381
NM_000435.2_ex5F agccctactcaggagagtcaga 60 55 288
NM_000435.2_ex5R acacagatgcagcagtccag 60 55 288
NM_000435.2_ex6F ctggactgctgcatctgtgt 61 55 281
NM_000435.2_ex6R cagagaaaacggccactcac 60 55 281
NM_000435.2_ex7F ctgcctatgacttctgcttacc 58 50 239
NM_000435.2_ex7R cctcctctcccctctttcc 60 63 239
NM_000435.2_ex8F acaccgatcgcactccat 60 56 220
NM_000435.2_ex8R accacccacctgccatac 60 61 220
NM_000435.2_ex9F gtagcccccgctttccta 60 61 185
NM_000435.2_ex9R gtcttttcgggctccctct 59 57 185
NM_000435.2_ex10F ctttctgggcctctgctcat 60 55 181
NM_000435.2_ex10R tcttgtcggactgtcattgg 60 60 181
NM_000435.2_ex11F gagctgaaccaggattggtc 60 55 358
NM_000435.2_ex11R cctccaggtgtgctgtttct 60 55 358
NM_000435.2_ex12F gccactccatgccatgtt 60 56 180
NM_000435.2_ex12R cgatctaaggaccccctctc 60 60 180
NM_000435.2_ex13F ccagggcccctttgtaac 60 61 234
NM_000435.2_ex13R agagggggcagtgtctgag 60 63 234
NM_000435.2_ex14F acctccctggcctgactac 61 63 209
NM_000435.2_ex14R tgcagagggaaggtgaggta 60 55 209
NM_000435.2_ex15F ctctcttccacccccaacag 60 60 170
NM_000435.2_ex15R atggagaggaggagggaaga 60 55 170
NM_000435.2_ex16F tgtaaccttgctccctaccc 60 55 229
NM_000435.2_ex16R atgactgtgttccccagagc 60 55 229
NM_000435.2_ex17F ggcaaggtaggtgaccagac 60 60 300
NM_000435.2_ex17R gagtccctgctctccaagc 60 63 300
NM_000435.2_ex18F ctccagctcctgcttcaatg 60 55 225
NM_000435.2_ex18R ccagtaactccacccacctg 60 60 225
NM_000435.2_ex19F cccaccccacagtactgact 60 60 201
NM_000435.2_ex19R atgctcccactcaccgatct 62 55 201
NM_000435.2_ex20F tcctgtgccactctcctctt 60 55 220
NM_000435.2_ex20R gcccccttacctcacacat 60 59 220
NM_000435.2_ex21F agtgggtccctctcttaccc 60 60 170
NM_000435.2_ex21R ctggcatacccagcgttc 60 61 170
NM_000435.2_ex22F ctcttgaccacccctcgtt 60 58 300
NM_000435.2_ex22R gccaacgcttacctgagaag 61 55 300
NM_000435.2_ex23F ccccattgtggctgatctac 60 55 195
NM_000435.2_ex23R cccctactcctcctccaaag 60 60 195
NM_000435.2_ex24_1F cttctcctccttccctccac 60 60 200
NM_000435.2_ex24_1R caggagggtcccgacaac 61 66 200
NM_000435.2_ex24_2F gttgtcgggaccctcctg 61 66 371
NM_000435.2_ex24_2R agcggctgttgttgaagag 59 53 371
NM_000435.2_ex25F agcccggtgtacgagaagta 60 55 344
NM_000435.2_ex25R gtcactcacccgatcacctc 60 60 344
NM_000435.2_ex26F gagacctgtgggtggagatg 61 60 396
NM_000435.2_ex26R ccctaagagcaggaagcaga 60 55 396
NM_000435.2_ex27F ccctctgcttcctgctctta 61 55 257
NM_000435.2_ex27R gcagggttctcacttcatgc 60 55 257
NM_000435.2_ex28F acatcccctcttcccattgt 60 55 150
NM_000435.2_ex28R gtcagaggagggggcaaag 60 63 150
NM_000435.2_ex29F cctgcccctccaggtaga 61 66 195
NM_000435.2_ex29R gaggggcactgtcactaacc 60 60 195
NM_000435.2_ex30F ttcctgctgacacactcctg 60 55 369
NM_000435.2_ex30R ccagctctgaggtccaaagt 59 55 369
NM_000435.2_ex31F tgctgcatccactctctgtc 60 55 214
NM_000435.2_ex31R tgacaccaacccagcttaga 60 50 214
NM_000435.2_ex32F gacctctctccccttcatcc 60 60 160
NM_000435.2_ex32R actgctgacacccagtggac 60 60 160
NM_000435.2_ex33_1F ctgacctctgtgggttctgg 60 60 311
NM_000435.2_ex33_1R gcctcctgctcttcttggac 61 60 311
NM_000435.2_ex33_2F gggtccaagaagagcaggag 59 60 327
NM_000435.2_ex33_2R agccacagggttcagcag 61 60 327
본 발명에서 디자인된 프라이머 (PRNP)
Primer ID 서열 Tm (oC) GC (%) 길이 (bp)
NM_001271561.1_ex1F cctgtcctccgagccagt 61 67 75
NM_001271561.1_ex1R gtttacctgcctcggtcgtg 62 60 75
NM_001080121.1_ex2_1F agcagtcattatggcgaacc 60 50 300
NM_001080121.1_ex2_1R ctgtgggtgccacctcct 62 67 300
NM_001080121.1_ex2_2F gaggtggcacccacagtc 61 67 352
NM_001080121.1_ex2_2R acgcgctccatcatcttaac 60 50 352
NM_001080121.1_ex2_3F ccgagaccgacgttaagatg 60 55 221
NM_001080121.1_ex2_3R cctccctcaagctggaaaa 60 52 221
이상으로 본 발명의 특정한 부분을 상세히 기술하였는바, 당업계의 통상의 지식을 가진 자에게 있어서 이러한 구체적인 기술은 단지 바람직한 구현 예일 뿐이며, 이에 본 발명의 범위가 제한되는 것이 아닌 점은 명백하다. 따라서, 본 발명의 실질적인 범위는 첨부된 청구항과 그의 등가물에 의하여 정의된다고 할 것이다.

Claims (12)

  1. 진단하고자 하는 개체로부터 분리된 생물학적 시료의 유전자 엑손(exon) 부위 돌연변이를 분석하는 단계를 포함하며, 상기 유전자 돌연변이는 하기 표 34의 돌연변이이고 각 유전자 당 적어도 하나의 돌연변이를 분석하는 것인 알츠하이머 진단을 위한 정보제공방법:
    [표 34]
    Figure 112019001260452-pat00003

  2. 제 1 항에 있어서, 상기 정보제공방법은 하기 표 35의 돌연변이 중 선택되는 1 이상의 유전자 돌연변이를 추가적으로 분석하는 단계를 포함하는 것인 정보제공방법:
    [표 35]
    Figure 112019001260452-pat00004

  3. 제 1 항에 있어서, 상기 생물학적 시료는 혈액, 정액, 질 세포, 모발, 타액, 소변, 구강세포, 태반세포 또는 태아세포를 포함하는 양수 및 이의 혼합물로 구성된 군에서 선택되는 시료로부터 분리된 DNA 시료인 것을 특징으로 하는 정보제공방법.
  4. 제 1 항에 있어서, 상기 돌연변이 분석은 상기 유전자에 상보적으로 결합하는 각각의 프라이머를 이용하여 유전자를 증폭하고, 상기 증폭산물의 시퀀싱(sequencing) 데이터를 이용하여 유전자 돌연변이를 분석하는 것을 특징으로 하는 정보제공방법.
  5. 제 4 항에 있어서, 상기 시퀀싱은 NGS (next generation sequencing) 방법인 것을 특징으로 하는 정보제공방법.
  6. 제 4 항에 있어서, 상기 유전자 증폭은 각 유전자에 대한 프라이머 세트를 1세트 이상 사용하는 것을 특징으로 하는 정보제공방법.
  7. 제 4 항에 있어서, 상기 유전자 증폭은 Emulsion PCR, Polony PCR, Bridge PCR 증폭 또는 멀티플렉스 PCR(Polymerase Chain Reaction) 증폭인 것을 특징으로 하는 정보제공방법.
  8. 제 1 항 또는 제 2 항에 있어서, 상기 정보제공방법은 PSEN2 (presenilin 2), CR1 (complement receptor 1), DNMBP (Dynamin binding protein), CD33 (sialic acid binding Ig-like lectin 3), MAPT (microtubule associated Tau protein), PARK7 (Parkinson disease protein 7), SNCA (Alpha synuclein), BIN1 (Bridging integrator 1), TREM2 (triggering receptor expressed on myeloid cells 2), BACE1 (Beta-secretase 1), PICALM (Phosphatidylinositol binding clathrin assembly protein), TDP43 (TAR-DNA binding protein-43), 및 SIGMAR1 (sigma non-opioid intracellular receptor 1)으로 구성된 군에서 선택되는 1 이상 유전자의 엑손(exon) 부위 돌연변이를 추가적으로 분석하는 단계를 포함하는 정보제공방법.
  9. APP (amyloid precursor protein), PSEN1 (presenilin 1), CLU (clusterin), SORL1 (sortilin-related receptor 1), LRP6 (low-density lipoprotein receptor-related protein 6), ADAM10 (Disintegrin and metalloproteinase domain-containing protein 10), ABCA7 (ATP-binding cassette transporter A7), LRRK2 (Leucine-rich repeat kinase 2), GRN(PGRN) (progranulin), 및 PRNP (prion protein gene) 유전자의 엑손(exon) 부위에 상보적으로 결합하는 각각의 프라이머를 이용하여, 하기 표 36의 유전자 돌연변이 중에서 각 유전자 당 적어도 하나의 돌연변이를 분석하는 것인 알츠하이머 진단 또는 예후 분석용 키트:
    [표 36]
    Figure 112019001260452-pat00005

  10. 삭제
  11. 삭제
  12. 삭제
KR1020170065179A 2017-05-26 2017-05-26 알츠하이머병 관련 30개 유전자를 이용한 유전적 진단방법 KR102040364B1 (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020170065179A KR102040364B1 (ko) 2017-05-26 2017-05-26 알츠하이머병 관련 30개 유전자를 이용한 유전적 진단방법

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR1020170065179A KR102040364B1 (ko) 2017-05-26 2017-05-26 알츠하이머병 관련 30개 유전자를 이용한 유전적 진단방법

Publications (2)

Publication Number Publication Date
KR20180130060A KR20180130060A (ko) 2018-12-06
KR102040364B1 true KR102040364B1 (ko) 2019-11-05

Family

ID=64671458

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020170065179A KR102040364B1 (ko) 2017-05-26 2017-05-26 알츠하이머병 관련 30개 유전자를 이용한 유전적 진단방법

Country Status (1)

Country Link
KR (1) KR102040364B1 (ko)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230032737A (ko) 2021-08-31 2023-03-07 가천대학교 산학협력단 Psen1 돌연변이 세포 및 이의 이용
KR20230032739A (ko) 2021-08-31 2023-03-07 가천대학교 산학협력단 App 돌연변이 세포 및 이의 이용

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109646668B (zh) * 2019-01-04 2019-10-18 厦门大学 一种多肽用于制备防治阿尔茨海默病药物的用途
MA54880A (fr) * 2019-02-01 2021-12-08 Avrobio Inc Compositions et procédés de traitement de troubles neurocognitifs
KR102078500B1 (ko) 2019-03-12 2020-02-17 건국대학교 산학협력단 알츠하이머병의 진단용 조성물
KR102256859B1 (ko) 2019-03-12 2021-05-27 건국대학교 산학협력단 알츠하이머병의 진단용 조성물
EP3981887A4 (en) * 2019-06-10 2023-11-08 Industry-Academic Cooperation Foundation, Yonsei University BIOMARRKERS FOR DIAGNOSING DISEASES OF THE CEREBRAL NERVOUS SYSTEM
KR102295114B1 (ko) * 2019-12-30 2021-08-27 경상국립대학교산학협력단 알츠하이머 병기 예측용 조성물 및 상기 조성물을 이용한 예측 키트
KR102364890B1 (ko) 2020-10-12 2022-02-18 경북대학교 산학협력단 알츠하이머병 관련 돌연변이 유전자를 포함하는 발현 카세트, 벡터, 이를 이용하여 형질 전환된 인간 전능성 줄기세포주와 이로부터 분화된 알츠하이머병 오가노이드 및 신경세포 모델
KR102489101B1 (ko) * 2021-01-12 2023-01-17 전남대학교산학협력단 항우울제 조기 치료반응이 불량한 남성 환자의 최종 비관해 예측용 바이오마커, 상기 바이오마커를 이용한 항우울제 조기 치료반응이 불량한 남성 환자의 최종비관해 진단에 대한 정보제공방법 및 진단키트
WO2022251658A1 (en) * 2021-05-28 2022-12-01 La Jolla Institute For Immunology T cell transcriptomic profiles in parkinsons disease, and methods and uses thereof
WO2023275376A1 (en) * 2021-07-02 2023-01-05 Aarhus Universitet Methods of treating alzheimer's disease
WO2024178386A1 (en) * 2023-02-24 2024-08-29 Aarhus Universitet Methods of treating endosomal trafficking diseases

Non-Patent Citations (12)

* Cited by examiner, † Cited by third party
Title
Annual Review of Neuroscience, 34:185-204 (2011)
Clinical Interventions in Aging, 11:1467-1488 (2016)
Clinical Interventions in Aging, 12:367-375 (2017.02.13.)
Clinical Interventions in Aging, 9:535-551 (2014)*
Eva Bagyinszky, "Genetic analysis of Korean patients with different kinds of neurodegenerative dementia", 가천대학교 바이오나노학과, 박사학위논문 (2014)
Journal of Clinical Laboratory Analysis, 30:1092-1099 (2016)
Neurobiology of Aging, 32:1990-1993 (2011)
Neurobiology of Aging, 56:212.e11-212.e17 (2017.04.26.)
Neurobiology of Aging, 56:212.e11-e212.e17 (2017.04.26.)
PLoS Medicine, 14(3):e1002270 (2017.03.28.)
The Open Neurology Journal, 5:8-11 (2011)
Vo Van Giau, "Genetic analysis of neurodegenerative diseases using next generation sequencing", 가천대학교 바이오나노학과, 박사학위논문 (2017.08.)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230032737A (ko) 2021-08-31 2023-03-07 가천대학교 산학협력단 Psen1 돌연변이 세포 및 이의 이용
KR20230032739A (ko) 2021-08-31 2023-03-07 가천대학교 산학협력단 App 돌연변이 세포 및 이의 이용

Also Published As

Publication number Publication date
KR20180130060A (ko) 2018-12-06

Similar Documents

Publication Publication Date Title
KR102040364B1 (ko) 알츠하이머병 관련 30개 유전자를 이용한 유전적 진단방법
Dwivedi et al. Diseases and molecular diagnostics: a step closer to precision medicine
KR102303638B1 (ko) 알츠하이머성 치매가 발병될 가능성 평가방법
EP3294903B1 (en) Method for in vitro diagnosis of dementia with lewy bodies using alphasynuclein gene transcripts
JP6723924B2 (ja) Pkd1遺伝子及びpkd2遺伝子のエクソンを増幅するためのプライマーセット及び方法
EP3607065A1 (en) Method and kit for constructing nucleic acid library
ES2546743A1 (es) Marcadores mitocondriales de enfermedades neurodegenerativas
Yu et al. Single nucleotide polymorphism rs1333049 on chromosome 9p21. 3 is associated with Alzheimer's disease in Han Chinese
GANGULY et al. Genetic testing for breast cancer susceptibility: frequency of BRCA1 and BRCA2 mutations
KR20200130165A (ko) Top3b 유전자 변이 기반 치매 진단방법
Van Giau et al. Optimization of specific multiplex DNA primers to detect variable CLU genomic lesions in patients with Alzheimer’s disease
JP5879665B2 (ja) PDE8A mRNA前駆体の編集プロファイリング:治療効力および/もしくは有効性または潜在的薬物副作用を診断するため、ならびに予測および評価するための、ヒト組織における特異的バイオマーカーとしてのADARs活性の使用
KR20160009397A (ko) 약제 내성 결핵균을 검출하는 방법
KR102481211B1 (ko) 만성 감각신경성 이명 진단용 snp 마커 및 이를 이용한 진단 방법
KR102280463B1 (ko) 백혈병 진단용 프라이머 세트 및 이를 이용한 백혈병 진단 방법
KR102063240B1 (ko) 폐암 환자의 변증 구분용 snp 마커 및 이의 용도
CN114752666B (zh) 替格瑞洛相关呼吸困难基因型检测试剂或试剂盒
JP2007166962A (ja) アルツハイマー病の予測または診断の方法
JP2007068429A (ja) Il−10多型検出による消化器系疾患罹患の判定方法およびそのキット
JP5648948B2 (ja) 低フォスファターゼ症の遺伝子変異スクリーニング方法
RU2808833C1 (ru) Способ преимплантационного генетического тестирования лице-лопаточно-плечевой мышечной дистрофии
WO2002024905A1 (fr) Procede permettant de determiner la mutation genetique
KR102152893B1 (ko) 간세포암종 특이 mlh1 유전자에 대한 순환 종양 dna 변이 검출 용도
de Souza Santos et al. High-Resolution Melting (HRM) for rapid MLST analysis of Neisseria meningitidis
Zhang et al. Whether Alzheimer’s diseases related genes also differently express in the hippocampus of Ts65Dn mice?

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E902 Notification of reason for refusal
E90F Notification of reason for final refusal
E701 Decision to grant or registration of patent right
GRNT Written decision to grant